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 INDUCTION OF INNATE AND ADAPTIVE IMMUNITY IN VIVO BY SELECTIVE 
ANTIBODY TARGETING OF POLY dA:dT AND ANTIGEN TO  
DENDRITIC CELLS 
 
Scott A. Barbuto, Ph.D. 
The Rockefeller University 2012 
 
Dendritic cells (DCs) have been shown to be efficient and specialized in antigen 
presentation, but innate stimuli have not been selectively delivered to determine if these 
cells alone can integrate innate and adaptive immunity in vivo.  Here we illustrate a novel 
method using expressed protein ligation (EPL) to attach the immune stimulant, poly 
dA:dT, to the DC uptake receptor, DEC205 (DEC). We will show that inoculation of α-
DEC-poly dA:dT fusion monoclonal antibodies (mAbs) is sufficient to induce rapid 
innate cytokine production by DCs. Adaptive T cell immunity is also elicited when the 
fusion mAb is given in combination with a DC-targeted antigen.  Forced entry is not 
required because α-DEC fusion mAbs deliver the poly dA:dT to its cytosolic targets.   
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Chapter I 
 
Introduction 
Since the human immunodeficiency virus (HIV) was discovered to cause Acquired 
Immunodeficiency Syndrome (AIDS) in 1984, there has been an urgency to create a 
vaccine to prevent the spread of disease.  Despite adequate information on the HIV 
genome and its proteins, researchers have failed to create candidate vaccines that induce 
the broad and long-lasting T cell-mediated immunity necessary for protection (Mascola et 
al., 2001).  Better vaccine delivery and vaccine adjuvants, or enhancers of immunity, are 
required to elicit vaccination.   
 
In contrast to humoral immunity which relies on B cells and their antibody products to 
react directly with native antigens, T-cell mediated immunity requires recognition of 
fragmented antigens displayed on infected cells’ surface membranes (Pamer et al., 1998).  
To elicit T cell immunity, vaccine antigens must be captured, processed, and bound to 
antigen presenting molecules, typically those of class I or class II MHC (Steinman et al., 
2002).  For this purpose, dendritic cell (DC) physiology can be exploited to improve 
vaccine antigen presentation. 
 
DCs are professional antigen presenting cells, necessary for maintaining tolerance and 
initiating immune responses (Steinman et al., 2002)..  It has been shown that a peptide 
sequence delivered specifically to dendritic cells is displayed 100 to 1000 times more 
effectively than a non-specific adjuvant (Hawiger et al., 2001).  Vaccine antigens can also 
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be targeted to specific antigen uptake receptors on DCs.  In this way, the vaccine can 
access the DC’s most efficient antigen processing receptors, in particular, receptors that 
can process the delivered antigen on both class I and class II MHC (Steinman et al., 
2002).  
 
However, to induce immunity and not tolerance, DCs must be activated when the specific 
antigen is delivered, making the use of adjuvants critical.  In this thesis, I develop a 
method to ligate poly dA:dT, an immune stimulant, to an antibody to the C-type lectin 
receptor, DEC205.  In this way, the poly dA:dT is delivered directly to the DCs that need 
to be stimulated for immunization of an antigen.  The anti-DEC205-poly dA:dT 
antibodies were examined for their capability to induce innate and adaptive immune 
responses in vitro and in vivo.  The implications of directly targeting the immune 
stimulant to the DCs are discussed.  
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Adjuvants 
Vaccination remains the most valuable tool for preventing infectious diseases.  The use of 
well-defined antigens for the generation of subunit vaccines has led to products with an 
improved safety profile.  However, purified antigens are usually poorly immunogenic, 
making essential the use of adjuvants (Ebensen et al., 2008).  However, only a handful of 
vaccine adjuvants are licensed for human use.  Thus, the development of new adjuvants, 
which are able to promote broad and sustained immune responses, remains a major goal 
in vaccinology (Ebensen et al., 2008).   
 
For more than 70 years, alum (aluminum salts) has been licensed as a vaccine adjuvant 
for prophylaxis in humans.  Today, alum is the most widely used adjuvant and is found in 
numerous vaccines, including HAV, HBV, HPV, Diptheria and Tetanus (DT), 
Haemophilus influenza type B (HIB), and pneumococcal conjugate vaccines (Mbow et. 
al., 2010).  Alum appears to work by increasing antigen uptake and stability at the site of 
injection (Morefield et al., 2005).  In addition, alum induces a local pro-inflammatory 
reaction that can increase immunogenicity (Goto et al, 1982 and 1997).  Several 
independent studies have shown that alum also activates NALP3, a component of the 
inflammasome complex, implicated in the induction of several proinflammatory 
cytokines (Eisenbarth et al, 2008, Kool et al., 2008, and Li et al., 2008).  However, it has 
also been demonstrated that the NALP3 pathway is dispensible for alum-mediated 
adjuvant activity in vivo (Franchi et al., 2008 and McKee et al., 2009).  Thus, it appears 
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that redundant pathways modulate the activity of alum in the host.  Although alum is the 
most widely used adjuvant, pre-clinical and clinical studies have shown that alum is often 
less potent than other adjuvants.  In addition, alum is a poor inducer of protective TH-1 
associated immune responses.  TH-1 response, or cell-mediated immunity, is 
characterized by the production of cytotoxic T-lymphocytes, macrophages, NK cells and 
cytokines, which are crucial for the development of vaccines against intracellular 
pathogens (Li et al., 2008). This is in contrast to TH-2 response, or humoral immunity, 
which involves the production of antibody molecules in response to antigen and is 
mediated by B-lymphocytes.  
 
The squalene-based oil-water emulsion, MF59, has been licensed in Europe for 
adjuvanted Flu vaccines since 1997.  This emulsion has been shown to increase 
hemagglutination inhibition (HI) titers and cross protection in both the elderly and the 
young (Podda et al., 2001).  In 2009, a clinical trial demonstrated that Avian H5 
pandemic flu vaccines containing MF59 were superior to alum-adjuvanted and non-
adjuvanted vaccine; MF59 containing vaccine had increased seroconversion and cross-
presentation, promoted CD4+ T cell response that predicts long term persistency of 
protective antibodies, and allowed for better recall responses in individuals boosted many 
years after their primary vaccination (Clark et al., 2009).  The mechanism of action for 
MF59 is to induce a local immunostimulatory environment at the injection site 
characterized by up-regulation of cytokines, chemokines, and other innate immunity 
genes (Mosca et al., 2008).  MF59 is also known to enhance antigen uptake by dendritic 
cells (Dupuis et al., 1998).   
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More recently, a new class of vaccine adjuvants have been designed that target the Toll-
Like-Receptor (TLR) pathways.  TLR receptors are essential to the role in the innate 
immune response.  They are single, membrane-spanning receptors that recognize 
structurally conserved molecules derived from microbes.  Activation of TLRs leads to the 
transcriptional activation of genes encoding for pro-inflammatory cytokines, chemokines, 
and co-stimulatory molecules, which subsequently control the activation of immune 
responses (Didierlaurant et al., 1998).   Table 1 summarizes the main antigens for the 
TLRs as well as some other important immune sensors. 
 
The TLR4 agonist, AS04 (3-O-desacyl-4’-monophosphoryl lipid A/MPL), is currently 
the only adjuvant of this type to be licensed; it has been approved for use against human 
papilloma virus and hepatitis (Harper et al., 2009).  Studies indicated that AS04 produced 
a transient and local activation of NF-kB activity and cytokine production, thus providing 
an innate immune signal for activation of antigen presenting cells (Didierlaurant et al., 
1998).     AS04 is adsorbed to alum, yet no synergistic effect between the two compounds 
was noted.  It appears, however, that the alum prolongs the cytokine response of AS04 at 
the injection site.   
 
There are numerous TLR agonists in pre-clinical and clinical trials for use as vaccine 
adjuvants (Mbow et al., 2010).  A TLR9 agonist, 1018 ISS, has been effective in boosting 
the recombinant hepatitis B surface antigen vaccine (Barry et al., 2007).  Another TLR9 
agonist based adjuvant, IC31, consists of a cationic peptide KLKL(5)KLK vehicle and  
 6 
 
 
 
 
 
 
 
 
Table 1:  PRRs and their ligands.  Pattern recognition receptors (PRRs) are proteins 
expressed by cells to identify pathogen-associated molecular patterns (PAMPs).  The 
table lists three types of PRRs:  Toll-Like Receptors (TLRs), Retinoic acid-inducible 
(RIG-I)-like receptors (RLRs), and C-type lectin receptors (CLRs). 
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Table 1 
 8 
the immunostimulatory oligodeoxynucleotide ODN1a sequence.  The complex between 
the bacterial peptide and ODN results in prolonged retention of antigen-adjuvant 
formulation and subsequent amplification of immune response.  This adjuvant is 
currently undergoing human clinical trials in a vaccine against TB (Agger et al., 2006 and 
Aagaard et al., 2009).  The small molecules imiquimod (TLR7 agonist) and resiquimod 
(TLR 7/8 agonist) were shown to improve the immunogenicity of a variety of vaccine 
adjuvants if adequately formulated or directly conjugated to protein antigens (Wille-
Reece et al., 2005)   
 
In addition to the TLR pathway, there are other innate pathways that could be exploited 
to design effective and potentially safe vaccine adjuvants.  The intracellular innate 
receptor, retinoic acid inducible gene I (RIG-I), is one possible candidate.  This receptor 
recognizes double-stranded RNA and initiates signaling cascades that lead to the 
activation of the protein kinases IKKαβ, TBK1, and IKKε and subsequent activation of 
the transcription factors NF-kB and IRF3 (Sen et al., 2005).  The activation of these 
transcription factors leads to the production of interferon alpha/beta and tumor necrosis 
factor alpha (TNF-α).  RIG-I is know to strongly bind poly I:C, poly A:U, and 5’ and 3’ 
untranslated regions of hepatitis C virus genomic RNA.  It does not bind dsDNA, 
poly(rA), or yeast tRNA (Yoneyama et al., 2007). 
 
Recently, Ablasser et. al described a novel pathway where poly dA:dT activated RIG-I in 
vitro.  In one key experiment, it was shown that knockdown of RIG-I significantly 
decreased the production of IFN-α in human monocyte derived dendritic cells (MoDCs) 
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when lipofectamine-transfected with poly dA:dT (Ablasser et al., 2009).  Furthermore, it 
was determined that RNA polymerase III was also essential for cytokine production in 
this assay.  It was concluded that RNA polymerase III transcribes poly dA:dT to poly 
(rA:rU), which then activates RIG-I (Ablasser et al. and Chiu et al., 2009).  This 
activation was abolished when RNA 5’-polyphospatase was present, indicating the 
importance of 5’-triphosphorylation.  Of note, the pathway appears to be different in 
humans and mice; knockdown of RIG-I does not significantly reduce the amount of IFN-
α in mouse dendritic cells (Ablasser et al., 2009).   Figure 1 depicts the pathway 
described above. 
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Figure 1:  Poly dA:dT Activation Pathway.   Poly dA:dT enters into the cytoplasm of a 
cell with the help of lipofectamine.  It is transcribed into poly (rA:rU) with 5’ 
triphosphorylation by RNA polymerase III.  The ds-RNA activates RIG-I, which in turn, 
activates IPS-1 on the mitochondria.  This activates the molecule TANK-binding kinase 1 
(TBK1) which interacts with STING to lead to gene transcription of IRF3 and IRF7 in 
the nucleus.  Type I interferon is produced and secreted from the cell.  
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 12 
One of the goals of this project was to produce a potential vaccine adjuvant that would 
activate RIG-I.  Since RIG-I is intracellular, delivery of poly dA:dT to antigen presenting 
cells is difficult.  To circumvent this problem, poly dA:dT was linked to the DEC205 
antibody.  DEC205 is a receptor on DCs that is primed for antigen presentation.  It is able 
to present both MHC class I and class II molecules; thus, it is said to be able to cross-
present.  As a result of this, it was speculated that poly dA:dT would be delivered to the 
cytoplasm of the immune cells when linked to the DEC205 antibody.   
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Dendritic Cells 
DCs were first recognized in 1973 for their unique morphology (Steinman et al., 1973).  
It took many years to convince the scientific community that DCs were distinct from 
macrophages, the best antigen presenting cell known at the time.  Now, DCs are known 
to be the most potent stimulators of immune reactions and effector T cell responses, 
orders of magntiudes better than macrophages (Steinman, R.M., 2007 and Nussenzweig 
et al., 1980).  
 
DCs can be found in both lymphoid and non-lymphoid tissues.  Although there is not a 
single unique feature that can distinguish all DCs, they are characterized by expression of 
CD11c and high levels of MHCII.  DCs consist of a heterogenous population that can be 
divided into several subsets (Edelson et al., 2010). 
 
Like all other immune cells, DCs originate from hematopoietic stem cells (Figure 1).  
Their half-life is short, and DCs are replaced by progenitors from the blood within 14 
days (Liu et al., 2007).  Although closely related, the development of DCs, monocytes, 
and macrophages is distinct.  In the bone marrow, macrophage and DC progenitors 
differentiate into either monocytes or common-DC-progenitors (CDPs) (Naik et al., 
2007).  CDPs no longer give rise to monocytes or macrophages, and they further 
differentiate into pre-DCs, losing the potential to produce plasmacytoid DCs (PDCs) 
(Naik et al., 2007). Pre-DCs leave the bone marrow, circulate in the blood, and seed 
lymphoid and non-lymphoid organs.  It is outside the bone marrow where these cells 
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differentiate into subsets of conventional DCs (Liu et al., 2007 and Bogunovic et al., 
2009). 
 
PDCs are very distinct from other DCs, known as conventional DCs.  PDCs are B220+ 
and CD11cint and produce large amounts of type I interferon upon CpG DNA or viral 
exposure.  PDCs are long-lived, do not display dendritic-like morphology, and finish 
their development in the bone marrow (Gillet et al., 2008 and Liu et al., 2005). 
 
Conventional DCs can be divided into two major subsets based on their expression of 
CD8.  The CD8+ subset is also positive for DEC205.  The CD8- DC subset includes a 
major CD4+ (CD11b+ and DCIR2+) population and a minor CD4- (double negative) 
population.  CD8- DCs reside in the marginal zone and red pulp of spleen whereas CD8+ 
DCs localize in the T cell area (Naik et al., 2007 and Arvadin et al., 2003).  
 
CD8- and CD8+ DCs both function in similar ways.  In the steady state, they both capture 
antigens and present them to T cells, ensuring tolerance by promoting regulatory T cell 
development or deletion and anergy of self-reactive T cells (Steinman et al., 2003).  They 
also have an innate sensing function, reacting to potential pathogens and changing the 
context in which they present antigens to T cells in order to initiate adaptive immune 
responses (Joffre et al., 2009).  Thus, CD8- and CD8+ DCs can both induce tolerance or 
immunity depending on the way in which they capture antigens. 
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Figure 2:  Dendritic Cell Morphology.  In the bone marrow, macrophage and DC 
progenitors differentiate into either monocytes or common-DC-progenitors (CDPs). 
CDPs further differentiate into pre-DCs, losing the potential to produce plasmacytoid 
DCs (PDCs).  Pre-DCs leave the bone marrow, circulate in the blood, and seed lymphoid 
and non-lymphoid organs where they differentiate into subsets of conventional DCs. 
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DEC205 Receptor 
DCs are both efficient and specialized in antigen presentation, and in addition, they 
control the magnitude, quality, and memory of the ensuing immune response (Steinman 
et al., 2002).  Receptors involved in the recognition and uptake of antigens into DCs are 
crucial for establishing a balanced immune response.  In particular, pattern recognition 
receptors such as C-type lectin receptors (CLRs) and Toll-like receptors (TLRs) have an 
important role in the recognition of antigens.  CLRs are important for the recognition and 
internalization of glycosylated antigens into intracellular compartments present in DCs, 
leading to processing and presentation on MHC molecules.  CLRs do not differentiate 
between glycans of self and non-self origin (van Kooyk, Y., 2008).  In contrast, TLRs are 
key receptors for the induction of intracellular signaling cascades after recognition of 
pathogens; TLR ligation leads to DC maturation and activation, often resulting in robust 
immune responses and induction of effector T-cells (Figdor et al., 2002).  CLR ligation 
does not necessarily result in the induction of effector T-cells, but facilitates the antigen-
presentation capacity of DCs.  Thus, uptake of antigen by CLRs without any TLR 
ligation may induce antigen-specific tolerance (van Kooyk, Y., 2008).   
 
DEC-205/CD205 (DEC) is a CLR with multiple external and contiguous carbohydrate 
recognition domains (Steinman et al., 2005).  It is a 205 kDa protein and a homologue of 
the macrophage mannose receptor (MMR) (Mahnke et al., 2000).  The amino termini of 
both MMR and DEC205 have two domains, one cysteine rich and the next fibronectin 
like, followed by 10 external contiguous carbohydrate recognition domains.  Both 
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receptors also have cytosolic domains with motifs for localization to coated pits and rapid 
entry into the cell (Jiang et al., 1995).  
 
Despite their similar structures, MMR and DEC205 were found to have different 
intracellular trafficking patterns.  DEC205 does not recycle through peripheral 
endosomes, like most recycling endosome receptors, but instead moves through late 
endosomes or lysosomes that are rich in MHC class II.  This feature of DEC205 was 
attributed to a triad of acidic amino acids in the cytosolic domain, and was shown to 
cause more efficient antigen presentation on MHC class II products relative to ligands for 
MMR (Figure 3) (Mahnke et al., 2000).   
 
In both human and mouse, DEC205 is expressed by thymic cortical epithelium and DC, 
but can also be detected on lymphocytes (Butler et al., 2007).  T cells, B cells and CD14+ 
monocytes were all characterized to have some level of expression for DEC205.  All 
subsets also carried mRNA for DEC205 (Kato et al., 2006).  Thus, DEC205 is widely 
expressed amongst hematopoietic subsets, but higher levels tend to be detected on cells 
with antigen presenting capability.  Although present on most leukocytes, DEC205 
showed low level of expression on monocytes, increased expression on immature DC, 
and greatly up-regulated expression on mature DC.  As it is an antigen uptake receptor, 
monocytes and immature DC possessed extensive intracellular compartments containing 
DEC205.  However, an analysis of mature DC revealed DEC205 staining to be 
predominantly at the cell surface with little intracellular staining.  This seems to indicate 
 19 
that, although mature DC has increased expression of DEC205, there is a down 
regulation of DEC205 mediated endocytosis (Butler et al., 2007).  
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Figure 3:  Structure of DEC205. 
 
 
 
 21 
 
Figure 3 
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The natural ligands for DEC205 are currently unknown, but antibodies have been used as 
surrogate ligands to perform a variety of studies.  In one of the first studies, ovalbumin 
(OVA) protein was linked to inter-heavy chain thiol groups on a DEC205 monoclonal 
antibody generated by mild reduction conditions.  After determining that the antibody 
was still functional, it was shown that OVA was presented by CD11c+ lymph node DCs 
to CD4+ and CD8+ T cells.  Presentation was at least 400 times more efficient than 
unconjugated OVA.  Furthermore, targeting anti-DEC205-OVA antibody to DCs in the 
steady state initially induced 4-7 cycles of T cell division, but the T cells were then 
deleted and the mice became specifically unresponsive to rechallenge with OVA in 
complete Freund’s adjuvant.  Thus, the anti-DEC205-OVA antibody induced tolerance 
when given in the steady state.  In contrast, when anti-DEC205-OVA antibody was 
simultaneously delivered with a DC maturation stimulus, strong immunity was induced.  
The CD8+ T cells responding to the antigen produced large amounts of IL-2 and IFN-γ, 
acquired cytolytic function in vivo, and responded vigorously to OVA rechallenge 
(Bonifaz et al., 2002). 
 
After the initial success of antigen delivery to dendritic cells via the DEC205 receptor, 
other antigens have been linked to the DEC205 antibody.  To induce tolerance, 
superagonist peptide MimA2 was linked to the DEC205 antibody.  MimA2 is an insulin 
peptide that is recognized by diabetogenic CD8+ T cells (Mukhopadhaya et al., 2008).  
The anti-DEC205-MimA2 antibody delivers MimA2 to DCs for presentation on class I 
MHC both in vivo and in vitro.  By selectively removing DCs from a transgenic non-
obese diabetic (NOD) mouse using diphtheria toxin, the group was also able to show that 
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DCs were required for this presentation.  Next, it was shown that the transferred β cell-
autoreactive CD8+ T cells were eventually deleted in response to the delivery of the 
MimA2 peptide.  Finally, it was shown that the anti-DEC205-MimA2 antibody induced 
peripheral CD8+ T cell tolerance in the NOD mice; the immunized mice did not undergo 
an immune response when challenged with a large dose of MimA2 peptide given in 
conjuction with complete Freund’s adjuvant (Mukhopadhaya et al., 2008). 
 
In 2006, Trumpfheller et. al. reported the effects of a DEC205 antibody with Gag p24 
fused to its heavy chain’s C-terminus.  The article indicated that such an antibody, when 
delivered with an adjuvant, was over 100 times more effective in inducing an immune 
response in mice when compared to other methods of using Gag as an antigen.  The anti-
DEC205-Gag p24 antibody also caused high frequencies of polyfunctional T cells, 
induced long-lived T cell memory, and elicited protective immunity at mucosal surfaces 
in mice (Trumpfheller et al., 2006).  In 2007, Bozzacco et. al. reported that the anti-
DEC205-Gag p24 antibody stimulated proliferation and IFN-γ production by CD8+ T 
cells isolated from the blood of HIV-infected donors (Bozzacco et al., 2007).  These 
findings have prompted the preparation for a Phase I clinical trial studying DEC205-Gag 
p24 antibody in the prevention of HIV transmission.   
 
Most recently, the human cancer antigen, mesothelin, was linked to the DEC205 
antibody.  Mesothelin, which is expressed on normal mesothelial cells, is overexpressed 
in several cancers, including mesothelioma, ovarian cancer, pancreatic adenocarcinoma, 
lung adenocarcinoma, uterine serous carcinoma, and acute myeloid leukemia (Hassan et 
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al., 2008).  Targeting human mesothelin to DEC205 receptor, in the presence of an 
adjuvant, induced stronger CD4+ T-cell responses compared to high doses of mesothelin 
protein.  CD4+ T cells were primed to produce IFN-γ, tumor necrosis factor (TNF)-α, and 
IL-2.  Targeting also resulted in cross-presentation to CD8+ T cells.  Thus, anti-DEC205-
mesothelin antibody could be valuable for enhancing immunity to mesothelin in cancers 
where this nonmutated protein is expressed (Wang et al., 2009).   
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Cross-Presentation 
Cross-presentation was discovered in the 1970s, when antigens from injected cells 
‘crossed’ into the MHC class I pathway of host antigen-presenting cells (APC), for naïve 
CD8+ cytotoxic T lymphocyte (CTL) priming (Figure 4) (Brevan et al., 1976).  Since its 
discovery, it has been determined that cross presentation is required for the defense 
against many viruses and tumors and is essential for vaccinations with protein antigens 
(Huang et al., 1994 and Sigal et al., 1999). 
 
DCs have been identified as the most relevant cross-presenting cells through experiments 
where in vivo depletion and functional inhibition of DCs compromises cross-priming 
(Kurts et al., 2001 and Jung et al., 2002).   Furthermore, the transcription factor, BATF3, 
which is expressed by CD8+ and CD103+ DCs, has been shown to be necessary for cross-
presentation in mice (Hildner et al., 2008).  Researchers have discovered that only a 
handful of endocytosis receptors are capable of cross-presentation: namely, Fc and 
certain CLRs, such as CLEC9A, CLEC7A, DC-SIGN, DEC205, and mannose receptor 1 
(Kurts et al., 2010). 
 
There have been two mechanistic explanations as to why a cell can cross-present.  The 
first hypothesis proposed that only cross-presenting DCs possess the antigen processing 
machinery that leads endocytosed antigen onto MHC class I molecules (Dudziak et al., 
2007).  Thus, only certain DCs have the ability for antigen escape from endosome into 
the cytoplasm to gain access to the proteasome and TAP transporters (Bryant et al., 
2004).  The second hypothesis proposed that cross-presenting DCs have specialized  
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Figure 4: MHC I and II Processing and Cross-presentation.  Top: MHC II 
processing.  The antigen is brought into the cell via endocytosis and processed into 
peptides.  The endosome then fuses with another endosome carrying the MHC II 
machinery produced in the ER.  Bottom:  MHC I processing.  The antigen is in the 
cytoplasm.  It is degraded into peptides in the proteasome.  The processed antigen is 
transported to the ER where it enters through TAP.  Here, it combines with MHC I 
machinery.  Cross-presentation occurs when the antigen “crosses” from the MHC II 
pathway into the MHC class I pathway. 
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Figure 4 
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phagosomes that contain MHC class I machinery.  Hence, the endocytosed antigen would 
not have to compete with loading of endogenous peptides in the ER, but instead would be 
brought to these phagosomes for MHC class I peptide presentation (Lin et al., 2008 and 
Villadangos et al., 2005).  It is still debated, however, how the loading machinery reaches 
the phagosomes (Kurts et al., 2010). 
   
Cross-priming CTLs specific for peripheral tissue antigens involves the cooperation 
between the different DC types.  Tissue DCs transport antigen from tissue to secondary 
lymphoid organs where resident CD8+ DCs cross-prime CTLs (Honey, K., 2005).  This 
antigen transfer mechanism allows for wider distribution of antigen and makes it possible 
for the signal to reach the draining lymph nodes; cross-presenting DCs are killed by the 
CTLs whereas the non-cross-presenting DCs can spread the message (Kurts et al., 2010). 
 
The activation of certain receptors, such as TLRs, leads to the upregulation of co-
stimulatory molecules and enhances cross-priming.  This is particularly true for TLR3 
and TLR9 activation (Wei et al., 2010).  Furthermore, activation of RIG-I and the 
inflammasome boost CTL responses, and indirect evidence suggests that these 
cytoplasmic sensors can stimulate cross-priming (Wei et al., 2010).  DCs also require 
specific TH cells for immunogenic cross-priming.  CTLs activated without T cells help 
lack expression of specific anti-apoptotic molecules, have a short life-span, and cannot 
carry out cytotoxic effector functions (Jung et al., 2002).  It remains unclear to what 
extent signaling events induced by TH cells or by TLRs overlap in cross-priming DCs.  
Some differences must exist, however, because TH cells and pattern-recognition 
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receptors synergistically activate DCs and both are necessary for optimal cross-priming 
(Kurts et al., 2001). 
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DNA-Protein Conjugates 
For years, researchers have developed methods to create DNA-protein conjugates (Figure 
5).  The generation of such semisynthetic conjugates is desirable because it allows the 
unique structure-directing properties of DNA to be combined with the almost unlimited 
variety of protein functionality.  DNA is readily accessible by synthetic chemical means 
and has high physicochemical stability.  DNA also possesses great mechanical rigidity, 
and nature provides numerous highly specific DNA-modifying enzymes that allow for 
processing and manipulation of the DNA with atomic precision (Niemeyer, C., 2010)  
Proteins have been tailored to perform highly specific functions, such as catalytic 
turnover, energy conversion, and translocation of components across membranes.  
Combined together, DNA-protein conjugates have a broad range of applications 
(Niemeyer, C., 2010). 
 
One of the first methods developed to generate semisynthetic DNA-protein conjugates is 
based on the high affinity of biotin-streptavidin binding.  Streptavidin has extreme 
chemical and thermal stability, making it possible to either chemically or genetically link 
it to a protein of interest (Wilcheck et al., 1990).  Biotinylated oligonucleotides are easily 
synthesized and commercially available.  Thus, the DNA-protein conjugate can be 
prepared by simple mixing the biotinylated DNA and the protein of interest conjugated to 
streptavidin.  Due to the high affinity of streptavidin-biotin interaction, dissociation is not 
an issue for this method.  However, streptavidin is tetrameric in nature, making it difficult 
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to control the stoichiometry of the respective DNA-protein conjugates (Wilcheck et al., 
1990).  
 
Another method for the generation of DNA-protein conjugates uses the specific 
interaction of a poly-histidine peptide (His-tag) with nickel(II) ions complexed by 
nitrilotriacetic acid (NTA) ligands.  With this approach, a hexahistidine tag is 
incorporated to the N- or C-terminus of the protein of interest (Meredith et al., 2004).  
Then, oligonucleotides are synthesized containing one, two, or three NTA groups.  The 
two compounds are then mixed together to create the DNA-protein conjugate.  
Dissociation constants of 120 and 6 nM are reported for the bisNTA- and trisNTA- DNA 
respectively (Goodman et al., 2009).  The benefit of this approach is that the linkage is 
relatively specific (note, as is often observed with His-tag based affinity purifications, 
non-specific binding will occur to some extent), and reversible; the linkage can easily be 
broken by a nickel chelator such as EDTA or imidazole.  However, this approach is not 
recommended when dissociation of the DNA from the protein of interest is not desirable. 
 
To make DNA protein conjugates, other affinity tags can be tethered to the DNA by 
solid-phase synthesis.  These tags can then be used as a hapten to specifically bind 
immunoglobulin G (IgG) antibodies raised against it (Kadkol et al., 1999).  For example, 
the chromophore fluorescein can be attached to DNA oligonucleotides to generate probes 
for the in vitro detection of complimentary nucleic acid sequences, by using anti-Fsc-IgG 
conjugated to a chromophore, fluorophore, or reporter protein.  Other hapten-antibody 
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pairs that have proven useful for this approach include biotin, dinitrophenol, digoxigenin, 
and short peptides such as FLAG tag (Knappik et al., 1994).  
 
A semisynthetic approach to DNA conjugation has also been developed for enzymes that 
contain nondiffusible cofactors.  In this case, the cofactors are extracted from the protein 
to yield the respective apoenzyme.  Then, the DNA moiety is attached to the cofactor, 
and the modified cofactor is reinserted into the apoenzyme (Niemeyer, C., 2010).  This 
approach was done with both apo-myoglobin and apo-horseradish peroxidase; the heme 
was modified with DNA, and the reconstituted enzymes were found to be fully functional 
and capable of specific hybridization with complementary nucleic acids immobilized on a 
range of surfaces (Fruk et al., 2006).   
 
To circumvent obstacles that result from the dissociation of noncovalent, reversible 
interactions, researchers have developed methods to covalently link the DNA to the 
protein of interest.  The most common approach involves maleimide coupling (Neimeyer 
et al., 1994).  A single cysteine is incorporated into the protein of interest.  Then, the 
protein of interest is reacted with a cross-linker bearing a maleimide functionality.  After 
purification, the maleimido-activated protein is treated with thiol-modified DNA 
oligonucleotides.  This results in the desired DNA-protein conjugate.  Of course, not all 
proteins of interest can be manipulated so that there is only one cysteine in its sequence.  
Hence, this approach is not always applicable (Joerger et al., 1995 and Kukolka et al., 
2004). 
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Expressed protein ligation offers a way to create DNA-protein conjugates without 
modifying the protein of interest’s sequence.  In this method, the protein of interest is 
genetically modified at its C-terminus with an intein domain.  Addition of low-molecular-
weight thiol compounds, such as mercaptoethanesulfonic acid (MESNA), leads to the 
cleavage of the intein from the protein of interest.  This leaves the protein of interest with 
a reactive α-thioester at its C-terminus.  It can then be ligated with a nucleic acid 
conjugate that has been engineered to have an N-terminal cysteine.  The result is the 
desired DNA-protein conjugate linked via a stable amide bond (Lovrinovic et al., 2003).   
 
Copper(I)-catalyzed Huisgen 1,3 dipolar cycloaddition of azides and alkynes (CuAAC) 
has also proven useful in the production of DNA-protein conjugates (Gramlich et al., 
2008).  In this approach, the enzyme protein-farnesyl transferase (PFTase) is used to 
specifically attach an azido-modified isoprenoid to a short recognition sequence that was 
fused to the protein of interest through genetic modification.  The azido groups are then 
coupled with alkyne-modified oligonucleotides in the presence of copper to generate the 
desired DNA-protein conjugate (Duckworth et al., 2007). 
 
Another approach to create DNA-protein conjugates uses the enzyme transglutaminase 
from Streptomyces mobaraensis, an enzyme that specifically catalyzes the acyl transfer 
reaction between a primary amine and the γ-carboxyamide group of glutamine 
(Tominaga et al., 2007).  The oligonucleotide was modified with 
carbobenzyloxyglutaminylglycine which functions as an acyl donor.  The protein of 
interest was genetically modified with a short peptide tag containing acyl-acceptor lysine 
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residues.  The DNA-protein conjugate was created when the modified DNA and protein 
were combined in the presence of the microbial enzyme (Tominaga et al., 2007). 
 
In yet another method, human O6-alkylguanine DNA-alkyltransferase is fused by genetic 
modification to the protein of interest.  This moiety is then treated with benzylguanine-
modified DNA oligonucleotides to produce the desired DNA-protein conjugate.  This 
approach has the advantage that no purification is required for the modified protein of 
interest.  The enzyme modified protein of interest was able to be conjugated to the DNA 
within crude E. coli lysate (Jongsma et al., 2006). 
 
At the outset of these studies, we expected that the best approach for the production of 
the anti-DEC205-poly dA:dT antibody is expressed protein ligation.  With this approach, 
a covalent bond is created between the DEC205 antibody and the poly dA:dT.  Thus, the 
dissociation between the antibody and poly dA:dT is not a factor.  In addition, the 
product should have well-defined stoichiometry and the linkage will be regiospecific.  
The DNA will always be attached to the heavy chain of the antibody’s C-terminus, and 
since there are two heavy chains per antibody, the DNA to antibody ratio will be 2:1 
(assuming the reaction goes to completion).  Finally, and perhaps most importantly, there 
is no extraneous sequence in between the poly dA:dT and the antibody.  Thus, any 
immune response elicited will be due to the poly dA:dT; the DEC205 antibody has been 
shown not to induce an immune response.   
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Figure 5:  Production of DNA-Protein Conjugates.  Strategies to link DNA to protein 
A.  A.  Biotin-streptavidin coupling.  B.  Ni-NTA-His6 conjugation.  C.  Antibody-hapten 
interaction.  D.  Cofactor reconstitution of apoenzymes.  E.  Malemide Coupling. 
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Expressed Protein Ligation  
In 1998, the method of expressed protein ligation (EPL) was introduced.  This approach 
requires the use of an intein, a segment of a protein that is able to excise itself and rejoin 
the remaining portions, termed the exteins, with a peptide bond (Muir, T.W., 2003).  A 
full length mutant intein (the mutant intein can only undergo the first step of protein 
splicing) is fused to the C-terminus of a recombinant protein.  After expression, the 
mutant intein is cleaved from the protein using a reactive thiol; this generates an α-
thioester at the C-terminus of the protein of interest.  This α-thioester can then undergo a 
chemoselective reaction with another protein where the N-terminal amino acid is a 
cysteine, i.e. native chemical ligation. There is an initial transthioesterification reaction 
followed by a spontaneous intramolecular S-N acyl shift to generate an amide bond 
between the two proteins (Figure 6) (Muralidharan et al., 2006).   
 
Several modified inteins can be used for the purpose of EPL.  One of the most commonly 
used inteins is the Mycobacterium xenopi DNA gyrase intein (Mxe GyrA).  This intein 
has several features that make it ideal for this method: it is relatively small and can be 
expressed efficiently in E. coli; it does not have special sequence preferences for the last 
residues of the N-extein fragment; the thiolysis reaction can be performed in the presence 
of detergents, organic solvents, and moderate amounts of denaturing agents; the GyrA 
intein can be efficiently refolded thus allowing recovery of intein-fusion proteins from E. 
coli inclusion bodies (Muir, T.W., 2003). 
 
 38 
 
 
 
 
 
 
 
 
 
Figure 6:  Mechanism of Expressed Protein Ligation (EPL).  The protein of interest 
(A) is expressed with a full length mutant intein attached to the C-terminus.  A reactive 
thiol is added to remove the intein, leaving A with a reactive α-thioester bond.  Protein A 
can then undergo native chemical ligation to a molecule (B) that has an N-terminal 
cysteine. 
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Expressed protein ligation has been applied to a wide variety of protein engineering 
problems.  In the simplest case, EPL allows the semisynthesis of a target protein from 
two polypeptide pieces.  This permits the incorporation of probes within the flanking 
regions of a protein (Muralidharan et al., 2006).  The approach can also be used to ligate a 
synthetic peptide to a recombinant protein.  This approach has been widely used to 
incorporate unnatural amino acids, post-translational modifications, and spectroscopic 
probes into many classes of proteins (Muir, T.W., 2003 and Schwarzer et al., 2005). Less 
commonly, EPL has been used to link together two recombinant proteins; this approach 
has proven useful in the production of cytotoxic proteins from innocuous fragments 
(Evans et al., 1998 and We et al., 2002).  
 
It was recently demonstrated that protein-intein fusions can be expressed in not only 
bacteria, but also a variety of eukaryotic cell lines.  Many proteins of interest, such as 
antibodies, require post-translational modifications that bacteria are not able to perform.  
Prior to the research of Singla et. al., it was unclear whether Mxe gyrA intein would be 
able to undergo thiolysis after protein-intein expression in systems other than bacteria.  
The group demonstrated that the extracellular domain of the Eph receptor with the Mxe 
gyrA intein attached was able to be expressed in both transfected mammalian HEK293 
cells and baculovirus infected insect cells (Singla et al., 2008).  In both cases, the fusion 
protein was secreted into the growth medium.  Critical to this result was mutation of 
cysteine 79 and 114 to serine in the Mxe GyrA intein sequence.  This was done to prevent 
formation of non-native disulfide bonds between the intein and the protein of interest – 
something that might occur in the oxidizing milieu or the ER/Golgi and the medium.  
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Thus, these mutations improved the fraction of correctly folded protein and thereby 
increased the cleavage efficiency of the intein when a reactive thiol was added (Singla et 
al., 2008). 
 
In 2003, EPL was proven effective in ligating nucleic acids to proteins of interest 
(Lovrinovic et al., 2003).  In these cases, nucleic acids are engineered so that they possess 
an N-terminal cysteine.  The nucleic acid is then ligated to the protein of interest that has 
a C-terminal α-thioester (Niemeyer, C., 2010).  In 2007, Lovrinovic et. al. published a 
paper monitoring the ligation of maltose binding protein (MBP) to cysteine-modified 
DNA oligomers.  Their results indicated that a pH of 8 to 8.5, an oligonucleotide/protein 
ratio of 1:4, and a reaction time of at least 12 hours were optimal for ligation.  
Furthermore, the reaction seemed unaffected by the amount of NaCl and Mg2+ in the 
ligation buffer (Lovrinovic et al., 2007).   
 
The main application of the resultant DNA-protein conjugates has been to perform 
immuno-PCR, a modification of the conventional enzyme-linked immunosorbent assay 
(ELISA).  In this procedure, the protein part of the DNA-protein conjugate is used to 
detect some type of antigen.  Then, the DNA moiety of the hybrid is amplified by PCR.  
The almost exponential amplification power of PCR results in the immuno-PCR method 
being about 1000-10000 fold more sensitive than ELISA (Burbulis et al., 2007).  
 
In the following research, EPL was used to make DNA-protein conjugates for a novel 
purpose; it was used to specifically target dendritic cells with an immune activating 
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agent.  Figure 7 shows the scheme in which anti-DEC205-poly dA:dT antibodies were 
made.  Briefly, the DEC205 antibody is expressed with an intein attached to the C-
terminus of its heavy chain.  The reactive thiol, sodium 2-mercaptoethanesulfonate 
(MESNA), is then used to remove the intein and leave the antibody with a reactive α-
thioester at its C-terminus.  Next, the antibody is allowed to react with short double 
stranded oligonucleotides that have an N-terminal cysteine to produce the antibody-DNA 
conjugates.  Finally, the DNA is elongated using klenow fragment.   
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Figure 7: Schematic of ligation procedure.  The DEC205 mAb is expressed with an 
intein attached to its heavy chain C-terminus.  The intein is then removed using MESNA.  
A 20 nucleotide oligomer of dA:dT with an N-terminal cysteine (cys-DNA) is ligated to 
the mAb’s activated C-terminus.  Klenow fragment is used to elongate the ligated DNA, 
producing the anti-DEC205-poly dA:dT mAbs. 
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Figure 7 
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Material and Methods 
 
Reagents   
Chloroquine and LPS were from Sigma-Aldrich (St. Louis, MO).  Human interleukin 4 
(IL-4) was from R&D systems (Minneapolis, MN).  Granulocyte-macrophage colony 
stimulating factor (GM-CSF) was from Berlex (Berkeley, CA).  Poly IC, Resquimod, and 
CLO were from InVivogen (San Diego, CA).  Klenow Fragment was from New England 
BioLabs (Ipswich, MA).  Amine-DNA oligomers were purchased from Fisher Scientific 
(Pittsburg, PA).  
 
Production of Fusion mDEC205-gyrA and hDEC205-gyrA Antibodies  
Mycobacterium xenopi gyrase A intein (gyrA) was cloned in frame after the C-terminus 
of anti-DEC205 heavy chain, as done previously for immune antigens such as HIV Gag 
p24 (Hawiger et al., 2001).  Briefly, the GyrA intein was cloned from a plasmid 
containing the gene for Mycobacterium xenopi gyrase A.  Quikchange Site-Directed 
Mutagenesis Kit (Stratagene, Santa Clara, CA) was used on this plasmid to obtain GyrA 
intein with cysteine 79 and 114 converted to serine.  Utilizing XhoI and NotI restriction 
sites incorporated into oligonucleotides primers, the fragment containing the Mxe GyrA 
(C79S C114S) was cloned into pK::hDEC205, a mammalian expression vector with both 
the heavy and light chain of human DEC205 antibody encoded within it.  The resultant 
vector produced DEC205 antibody with GyrA fused to the C-terminus of that antibody’s 
heavy chain (Figure 8).  The identity of the cloned fragment was confirmed by DNA 
sequencing (data not shown).  To determine if the anti-DEC205-Mxe GyrA (C79S  
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Figure 8:  Plasmid map of the anti-DEC205-Mxe GyrA intein antibody.  Mxe GyrA intein 
was cloned in frame to the DEC205 heavy chain’s C-terminus using restriction sites, XhoI and 
NotI.  The resultant plasmid, when incorporated into HEK293T cells, produces the DEC205 
antibody with the Mxe GyrA intein attached to it. 
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Figure 8 
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C114S) intein antibody was expressed, the recombinant vector was used to transiently 
transfect HEK 293T cells via calcium phosphate in serum-free DMEM media 
supplemented with Nutridoma SP (Roche, Indianapolis, IN) (Wang et al., 2009).  After 
the 293T cells were allowed to express the anti-DEC205-Mxe gyrA (C79S C114S) intein 
antibody for three days, the medium was collected and filtered with Steritop vacuum 
filter cups (Millipore, Billerica, MA).  The medium was then loaded onto a column 
containing 1 mL of protein G sepharose beads (GE Healthcare, Piscataway, NJ).  The 
beads were washed with 200 mL of Protein G binding buffer (Pierce, Rockford, IL).  The 
anti-DEC205-Mxe gyrA (C79S C114S) intein antibody was then eluted off the beads 
using Protein G elution buffer (Pierce, Rockford, IL).  The antibody was dialyzed against 
phosphate buffered solution (PBS) and concentrated using amicon concentrators 
(Millipore, Billerica, MA).  The integrity of the purified proteins was determined by 
SDS-Page Coomasie blue and western-blot analysis using rat anti-human IgG Ab 
conjugated with HRP (Jackson Immunoresearch, West Grove, PA).  The typical yield for 
the preperation ranged from 1.25 to 2.5 mg/L. 
 
Mxe GyrA (C79S C114S) intein was cloned in frame to a mammalian expression vector 
that encoded the heavy and light chain of anti-mouse (m) DEC205 antibody.  The 
resultant vector produced mDEC205 antibody with GyrA fused to the C-terminus of the 
antibody’s heavy chain.  Anti-mDEC205-Mxe gyrA (C79S C114S) intein antibody was 
then produced and purified in the same manner as described above for anti-human 
(h)DEC205-Mxe gyrA (C79S C114S) intein antibody.  The integrity of the purified 
proteins was determined by SDS-Page Coomasie blue and western-blot analysis using 
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goat anti-mouse IgG Ab conjugated with HRP (Jackson Immunoresearch, West Grove, 
PA).  The typical yield for the preperation ranged from 1.5-3 mg/L. 
 
Control antibodies were also produced.  Mxe GyrA (C79S C114S) intein was cloned in 
frame to a mammalian expression vector that encoded the heavy and light chain of anti- 
mouse IgG (mControl) antibody and anti-human IgG (hControl) antibody.  The resultant 
vectors were used to produce and purify anti-mControl and anti-hControl Mxe GyrA 
(C79S C114S) intein antibodies, respectively.  The integrity of the purified proteins was 
determined by SDS-Page Coomasie blue and western-blot analysis using either rat anti-
human IgG or goat anti-mouse IgG Ab conjugated with HRP (Jackson Immunoresearch, 
West Grove, PA).  The respective yields of anti-mControl and anti-hControl gyrA (C79S 
C114S) antibodies ranged from 1.0-2.5 and 1.0-2.0 mg/L). 
 
Mxe GyrA (C79S C114S) intein was also cloned in frame to a mammalian expression 
vector that encoded the heavy and light chain of anti-DCIR2 antibody.  The resultant 
vector was used to produce and purify anti-DCIR2 Mxe GyrA (C79S C114S) intein 
antibodies.  The integrity of the purified protein was determined by SDS-Page Coomasie 
blue and western-blot analysis using goat anti-mouse IgG Ab conjugated with HRP 
(Jackson Immunoresearch, West Grove, PA).  The respective yield of anti-DCIR2 Mxe 
gyrA (C79S C114S) intein antibody was 1.25 mg/L. 
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Production of Short Fluorescent Peptide  
Fmoc-based solid phase peptide synthesis (SPPS) was used to produce a peptide of 
sequence H-Cys-Gly-Lys(Fluorescein)-Gly-NH2.  The following amino acids were used: 
Fmoc-Gly-OH, Fmoc-Lys(Mmt)-OH, and Fmoc-Cys(StBu)-OH (Sigma Aldrich, St. 
Louis, MO).  The sequence was assembled on a Rink amide resin (Merck, Whitehouse 
St., NJ) using HBTU (Sigma Aldrich, St. Louis, MO) as the activating agent and 20% 
piperdine/dimethylformamide (DMF) for Fmoc deprotection.  Following chain assembly, 
the lysine side-chain was deprotected with 5x3 minute treatments of 1% trifluoroacetic 
acid (TFA), 5% N,N'-Diisopropylcarbodiimide (DIC), and 94% Dichloromethane 
(DCM).  Carboxyfluorescein was then coupled to the lysine using DIC/N-
hydroxysuccinimide activation.  Next, the Fmoc and StBu protecting groups on the 
cysteine were deprotected using 20% piperdine/DMF and phosphine hydrochloride, 
respectively.  Finally, the peptide was cleaved off the resin using 95% TFA, 2.5% 
triisopropylsilane (TIS) and 2.5% H2O solution.  The peptide was purified by reverse-
phase HPLC (Figure 9).  Mass spectrometry was used to identify the fraction with the 
correct peptide (Figure 9).   
ESI-MS: 721.42 (Calculated); 721.0 ± 1.0 (observed). 
HPLC retention time: 16.4 minutes (C18 Yvdac column, Buffer A: 0.1% TFA in water, 
Buffer B:  90% CH3CN, 0.1% TFA in water, 0-73% solution B over 30 min, 1 mL/min). 
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Figure 9:  Production of short fluorescent peptide.  A. A peptide with a sequence of 
H-Cys-Gly-Lys(Fluorescein)-Gly-NH2 was synthesized using Fmoc-based solid phase 
peptide synthesis (SPPS).  After production, the sample was then run through a C18 
Yvdac column.  (Right) The 280 nM absorbance trace on the HPLC.  The main peak was 
collected and analyzed via ESI-Mass Spectrometry (Left).  
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Figure 9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
Production of Cys-DNA 
A DNA oligonucleotide with an N-terminal amine group was purchased from Fisher 
(Pittsburg, PA).  The sequence is (AminoC6)AAAAAAAAAAAAAAAAAAAA where 
aminoC6 is .  Fmoc-Cys(StBu)-OH (Sigma, St. Louis, 
MO) was activated with N-hydroxysuccinimide (Fmoc-Cys(StBu)-OSU) using DIC.  
Next, the amino-DNA was reacted with 50 fold excess Fmoc-Cys(StBu)-OSU in a 1:1 
solution of 50 mM borate buffer pH 8.5 and dimethylformamide (DMF) (Figure 10A).  
The protected Cys-DNA was purified by HPLC using a C18 Vydac column where buffer 
A was 10 mM triethylamine/acetate (TEAA) in water and buffer B was 80% CH3CN in 
water.  A gradient of 0-50% B over 30 minutes was used for purification (Figure 10B).  
Next, the protected Cys-DNA was incubated overnight in 30% ammonium hydroxide to 
remove the Fmoc group on the cysteine.  Finally, the sample was placed in 1 M 
dithiothreitol (DTT) to remove the t-butyl group that protected the side chain group of the 
cysteine.  The deprotected Cys-DNA was purified using the same HPLC gradient as 
before.  The desired product was confirmed by MALDI mass spectrometry (Figure 11).   
HPLC Retention Times:  unmodified DNA oligonucleotide (22.8 minutes), Fmoc-
Cys(StBu)-OSU (41 minutes), Cys(StBu)-OSU hydrolysis (35 minutes), protected Cys-
DNA (30.2 minutes), deprotected Cys-DNA (21.2 minutes). 
MALDI-MS for deprotected Cys-DNA: 6483.4 (calculated); 6495.73 ± 83.66 (observed)  
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Figure 10:  Production of Cys-DNA.  A.  Schematic of reaction to produce protected 
cys-DNA.  Protected cysteine was activated with N-hydroxysuccinimide (Fmoc-
Cys(StBu)-OSU).  Amino-DNA was reacted with 50 fold excess of this moiety in a 1:1 
mixture of 50 mM borate buffer, pH 8.5 and DMF.  B. HPLC trace of Cys-DNA 
purification.  Buffer A: 10 mM triethylamine/acetate (TEAA).  Buffer B:  80% 
acetonitrile (Acn).  A gradient of 0-50% B over 30 minutes was used for purification.  
Peaks are labeled accordingly. Fmoc-Cys(StBu)-OSU is Amino Acid. 
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Figure 11:  MALDI Spectrum of Cys-DNA. The matrix for the sample was 10:1 50 
mg/mL hydroxy-picolinic acid (HPA) to 50 mg/mL ammonium citrate.  MALDI-MS for 
deprotected Cys-DNA: 6483.4 (calculated); 6495.73 ± 83.66 (observed)  
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Expressed Protein Ligation  
An oligonucleotide of sequence TTTTTTTTTTTTTTTTTTTT was purchased from 
Fisher (Pittsburgh, PA).  It was combined in a 1:1 ratio with Cys-DNA in water and then 
annealed to the Cys-DNA by heating to 95°C for 5 minutes and allowed to gradually cool 
to room temperature for 1 hour.  Fusion antibodies were activated by the addition of 100 
mM sodium 2-mercaptoethanesulfonate (MESNA) (Sigma, St. Louis, MO) for 18 hours 
in PBS.  At a concentration of 50 µM, the activated antibody was reacted with 500 µM of 
double stranded (ds)-Cys-DNA in ligation buffer (1x PBS, 400 mM NaCl, 6 mM TCEP, 
1 mM EDTA, 100 mM MESNA, pH 7.5).  The sample was allowed to react at room 
temperature overnight.  Reaction progress was monitored by gel electrophoresis using 2-
20% TBE native gels (Bio Rad, Hercules, CA), and then staining with ethidium bromide 
(InVitrogen, Carlsbad, CA) to check for ligation.  After ligation, the sample was dialyzed 
5 times against PBS for at least 2 hours each time at 4°C using Slide-A-Lyzer Cassettes, 
20,000 molecular weight cut-off (MWCO) (Pierce, Rockford, IL).  100,000 MWCO 
microcon concentrators (Millipore, Billerica, MA) were then used to concentrate the 
sample.  Trace amounts of cys-DNA were usually still seen at this point as visualized on 
the 2-20% TBE native gels stained with EtBr.  If necessary, the samples were diluted to 1 
mL and reconcentrated (5 mg/ml) until no Cys-DNA was visible on the EtBr gel (usually 
2 times).  Approximately 30% of the antibody (.3 mg from 1.0 mg) is lost from this 
purification procedure. 
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Elongation   
3.2 µM of purified DNA-antibody conjugates were reacted with 5 µM Klenow fragment 
(New England BioLabs, Ipswich, MA) in the presence of 0.3 mM dATP and dTTP for 90 
minutes in NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl, 10 mM MgCl2, 
1 mM Dithiothreitol).  Aliquots of the antibodies were then removed and treated with 0.1 
µg/mL proteinase K (Qiagen, Valencia, CA) for 1 hour and run on a 2% agarose gel 
stained with EtBr to check for elongation.  For preparative scale, 1 mL (320 µg of 
antibody) reactions were used.  The sample was then purified and concentrated using the 
100,000 MWCO microcon concentrators (Millipore, Billerica, MA).   
 
CHO Staining 
CHO cells stably transfected to produce hDEC205 or mDEC205 receptors as well as 
naive CHO cells (CHO NEO) were plated.  Cells were spun down and placed into 50 µL 
of FACS buffer (PBS pH 7.4 containing 2% fetal calf serum (FCS) and 0.02% NaN3) 
with 2 µM EDTA.  Then, 2 µg, 0.2 µg, and 0.02 µg of the anti-DEC poly dA:dT mAb 
was added independently to both cells types.  After a 20 minute incubation at 4 ºC, the 
cells were spun down and washed three times with FACS buffer with 2 µM EDTA.  An 
hIgG-PE or mIgG-PE antibody was then diluted 1:250 into the cells.  After another 20 
minute incubation at 4 ºC, the cells were washed twice with FACS buffer with EDTA.  
Flow cytometry was then performed on the cells to determine the extent of hDEC205 and 
mDEC205 binding to its corresponding receptors.   
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Human Cell Isolation and Culture   
Human PBMCs were isolated from whole blood of healthy volunteers by density gradient 
centrifugation using Ficoll-Hypaque (GE healthcare, Piscataway, NJ).  Human 
monocytes were isolated from PBMCs with anti-CD14 paramagnetic beads (Miltenyi 
Biotec, Auburn, CA) and were differentiated for 5 days into MoDCs in the presence of 
IL-4 (20 ng/mL) and GM-CSF (20 ng/mL).  Primary cells were cultured in RPMI 
(GIBCO, Carlsbad, CA) media supplemented with 2% pooled human serum (GemCell, 
Pennant Hills, NSW).  293T cells were cultured in DMEM (GIBCO, Carlsbad, CA) with 
10% FCS (Omega Scientific, Tarzana, CA), L-glutamine (GIBCO, Carlsbad, CA), and 
HEPES (Lonza, Walkersville, MD).   
 
Mice   
C57BL/6 mice were from Harlan (San Francisco, CA).  DEC205 KO and human DEC 
transgenic mice were obtained from M. Nussenzweig (The Rockefeller University, New 
York).  CD11c-DTR mice were produced as described previously.80  To produce 
chimeras, B6 or DEC205 KO mice were irradiated twice 3 hours apart with 550 rads for 
4 minutes.  3 hours after the last irradiation, mice were given either DEC205 KO or B6 
bone marrow intravenously.  The mice were given sulfatrim and antibiotic water 
(Neomyocin) for at least two weeks until use.  Mice were maintained under specific 
pathogen-free conditions and used at 7-8 week of age according to Institutional Animal 
Care and Use guidelines. 
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In vivo Cytokine Secretion   
Mice were injected i.p. with poly I:C or anti-DEC205-poly dA:dT mAb, and serum was 
collected after 6 hours.  Production of IFN-α (PBL Interferon Source, Piscataway, NJ) 
was determined by ELISA following manufacturer’s instructions. 
 
Cell Sorting  
Spleens were cut in small pieces and incubated at 37 ºC for 30 minutes in Hank’s 
medium supplemented with 400 U/mL Collagenase D (Roche Diagnostics, Indianapolis, 
IN).  5 mM EDTA was added for the last five minutes.  Cells were washed and then 
resuspended in 1x RBC lysis buffer (eBioscience, San Diego, CA).  After 1 minute, the 
cells were washed and stained with CD8-APC, CD11c PE-Cy7 (eBioscience, San Diego, 
CA), and Live/Dead Fixable Aqua viability dye (Invitrogen, Carlsbad, CA).  Different 
populations were isolated by sorting on a FACSAria with DiVa configuration.  Three 
populations (CD11clow, CD8+ DCs, and CD8- DCs) were then plated at 300,000 cells/mL 
in RPMI supplemented with 5% FCS.  The next day, the supernatant was collected and 
an IFN-α ELISA was performed following manufacturer’s instructions. 
 
Targeting of Alexa 647-Labeled mAbs   
Anti-mDEC205-poly dA:dT mAb was labeled with Alexa 647 (Invitrogen Carlsbad, CA) 
per the manufacturer’s instructions.  C57BL/6 mice were injected i.p with 10 µg labeled 
mAb.  Uptake of labeled mAb by splenocytes was evaluated 3 hours after inoculation by 
multicolor flow cytometry (Idoyaga et al., 2009).  The gating strategy is shown in figure 
12.   
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Figure 12:  Gating strategy for evaluating the targeting of injected anti-DEC205-poly 
dA:dT mAb to different subsets of DCs and other leukocytes in mouse spleen.  
Splenocytes were incubated with anti-CD19 microbeads to remove B cells.   Non-B cells 
(A and B) or positive selected B cells (C) were stained to detect distinctive leukocyte 
populations.  A.  Scheme to detect T cells, CD8- DCs, CD8+ DCs, PDCs, red pulp 
macrophages, granulocytes, and monocytes.  B.  Scheme to detect NK cells.  C.  Scheme 
to detect B cells.81 
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Figure 12 
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DC Maturation   
Mice were injected i.p. with PBS or 15 ug anti-DEC205-poly dA:dT mAb.  Spleens were 
collected 12 hours later and collagenase digested.  Maturation was monitored by 
increased expression of MHC-II, CD86 and CD40 after gating on plasmacytoid, CD11chi 
DEC-, or CD11chi DEC+ DCs (Idoyaga et al., 2009).  The gating strategy to obtain these 
populations  was the same as shown in figure 12. 
 
Immunizations 
Mice were immunized twice i.p. at 4 week intervals with 5 µg of fusion HIV gag-p24 
mAbs together with adjuvant (poly I:C or anti-DEC205-poly dA:dT mAb).  One week 
after the second injection, splenocytes were restimulated with p24 (2 µM) or negative 
control peptide mix, along with 2 µg/mL of costimulatory αCD28 (clone 37.51) for 6 
hours.  Brefeldin A (10 ug/mL; Sigma-Aldrich, St. Louis, MO) was added for the last 5 
hours.  Cells were washed, incubated for 10 min at 4ºC with 2.4G2 mAb to block Fcγ 
receptors, washed, and stained with Live/Dead Fixable Aqua viability dye, Pacific blue-
conjugated anti-CD3, PerCP-conjugated anti-CD4, and Alexa 750-conjugated anti-CD8 
mAbs for 20 min at 4ºC.  Cells were permeabilized (Cytofix/Cytoperm Plus; BD 
Biosciences, Bedford, MA) and stained with APC-anti-IFNγ, PE-anti-IL2, and PE-Cy7 
anti-TNFα mAbs for 15 min at room temperature (BD Biosciences, Bedford, MA).  
Samples were acquired on BD LSRII flow cytometry and analyzed with FlowJo Software 
(Tree Star, Inc., San Carlos, CA). 
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RNA Preparation and RT-PCR   
Human MoDCs were collected 24 hours after electroporation with various siRNA.  Cells 
were lysed with TRIzol (Invitrogen, Carlsbad, CA), followed by one round of chloroform 
extraction.  Total RNA was precipitated with isopropanol and then washed with 75% 
ethanol.  Reverse transcription was then performed on isolated RNA using High Capacity 
RNA-to- cDNA Kit (Applied Biosystems, Carlsbad, CA).  RT-PCR conditions and 
primer sequences for RIG-I and MDA-5 were previously described (Sasai et al., 2006). 
 
ELISA   
Human IFN-α, mouse IFN- α, human IFN-β (PBL Interferon Source), and human TNF 
(R&D systems) were assessed with commercial ELISA kits according to the 
manufacturer’s instructions.   
 
Electroporation with SiRNA 
  All siRNA sequences were purchased from Sigma.  The RIG-I siRNA sequence was 5’-
AAGGCUGGUUCCGUGGCUUUUdTdT-3’.  The MDA5 siRNA sequences were: 5’-
GUUCAGGAGUUAUCGAACAdTdT-3’, 5’-GUAACAUUGUUAUCCGUUAdTdT-3’, 
5’-GGUGUAAGAGAGCUACUAAdTdT-3’.  The Control siRNA (targets luciferase) 
sequence was 5’-CUUACGCUGAGUACUUC GAdTdT-3’.  For electroporation, human 
MoDCs were resuspended in opti-MEM without phenol red (Invitrogen) at a 
concentration of 4 x 107 per milliliter.  4 x 106 cells were electroporated with 1 nmol of 
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siRNA in a 4 mm cuvette and in a total volume of 200 ul of opti-MEM.  Cells were 
pulsed using the ECM830 Electro Square PoratorTM (BTX Harvard Apparatus).  The 
pulse conditions were a unique square wave pulse of 500 V and 0.5 ms.  Immediately 
after electroporation, cells were transferred in complete medium [RPMI 2% human 
serum] supplemented with GM-CSF (20 ng/mL) and IL-4 (20 ng/mL).   
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Chapter 3 
 
Results 
 
Production of anti-DEC205-poly dA:dT Antibodies 
At the onset of the project, two methods were employed to ligate molecules of interest to 
the DEC205 antibody: one method used the full-length mutant intein, Mxe GyrA, and the 
other used split inteins, either DNAe or NPU.  The use of split inteins proved difficult.  
The anti-DEC205-DNAe intein was not produced in the media of transiently transfected 
HEK293T cells, and only a small amount (0.1-0.2 mg/L) of anti-DEC205-NPU intein 
was found in the media of transiently transfected HEK293T cells.  Thus, only the full-
length mutant intein method was utilized to produce the anti-DEC205-poly dA:dT 
antibodies. 
 
The overall scheme of production is shown in Figure 13.  The anti-DEC205-Mxe gyrA 
intein antibodies were produced by transient transfection in HEK293T cells.   After 3-5 
days of expression, the secreted antibody in the media was loaded onto a Protein G 
column for purification.   The antibody was then dialyzed against PBS to produce the 
purified anti-DEC205-intein antibodies.   
 
The integrity of the purified proteins was confirmed by 10% SDS-Page gel stained with 
Coomassie blue (Figure 14A) and Western blot analysis (Figure 14B) using rat anti- 
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Figure 13:  Schematic of Production.  DNA encoding the DEC205 antibody with the 
Mxe gyrA intein attached to its C-terminus is transiently transfected into HEK293T cells.  
After 3-5 days of expression, the media is collected, and the antibody is purified using a 
column of Protein G beads.  The antibody is dialyzed in PBS to produce the purified anti-
DEC205-Mxe gyrA intein antibodies.  This antibody is then incubated with 100 mM 
MESNA for 24 hours.  The MESNA-treated antibody is combined with ds-Cys-DNA in 
order for expressed protein ligation to occur.  The DNA-antibody conjugate is purified 
from unreacted Cys-DNA by dialysis and concentration.  The DNA on the purified DNA-
antibody conjugate is elongated using Klenow fragment.  The anti-DEC205-poly dA:dT 
antibodies are purified using dialysis and concentration. 
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Figure 13 
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human (left panel) or goat anti-mouse (right panel) IgG Ab conjugated with HRP.  The 
results indicated that the anti-DEC205-Mxe gyrA intein antibody was produced. The anti-
hIgG (left) and mIgG (right) western blot showed two bands.  The most prevalent band 
was at ~75 kD and represents that DEC205 antibody’s heavy chain with the Mxe GyrA 
intein attached to the C-terminus.  The band at ~50 kD can be interpreted as a non-
specific IgG contaminant, or the DEC205 antibody without the intein attached.  It is most 
likely the latter.  The anti-DEC205-intein antibodies were produced in media 
supplemented with nutridoma.  Nutridoma, unlike serum, does not have antibodies, and 
therefore, the media should not have IgG contaminants.  The Coomassie blue stain 
showed three main bands.  This includes the two bands described above, and a band at 
~25 kD which is the right size for the light chain of the DEC205 antibody.  Since there 
are only three bands on the Coomassie blue stain, the DEC205-Mxe GyrA intein antibody 
production is relatively pure.  A negative control is shown in lane 5.  This is expression 
of the DEC205 antibody without the Mxe GyrA intein attached to its C-terminus.  As 
expected, only 2 bands appear in this lane: the 50 and 25 kD bands.  This gives further 
support that the ~75 kD band is the DEC205-Mxe GyrA intein antibody band. 
 
To evaluate the best method of transfection, different concentrations of the anti-DEC205-
GyrA C79S C114S DNA were used to transfect the HEK293T cells.  A total of five 
different concentrations were used: 5, 10, 15, 20, and 30 µg of DNA per plate.  This was 
performed because the typical amount of DNA transfected, 30 µg, appeared to be killing 
the HEK293T cells as visualized by microscopy.  The yield obtained from the plates 
transfected with 30 µg was approximately 0.75 mg/L.  The best yield was obtained using  
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Figure 14:  Production of DEC205-Mxe GyrA intein antibodies.  A & B.  The 
integrity of the anti-DEC205-intein antibodies were confirmed by 10% SDS-Page gel 
stained with (A) Coomassie blue and (B) Western blot analysis using (Left) anti-human 
(h) or (Right) anti-mouse (m) IgG Ab conjugated with HRP.  Numbers are expressed in 
kDa.  Anti-hIgG (hControl) and anti-mIgG (mControl) Mxe GyrA intein antibodies were 
also produced.  C.  Time course of MESNA treatment for anti-hDEC205-intein 
antibodies.  Top numbers represent time in hours.  Left numbers represent kDa.  D. 
Activation of the DEC205 antibody.  Anti-DEC-intein antibodies were treated with 100 
mM MESNA for 18 hours.  The removal of the intein from the heavy chain was 
confirmed by 10% SDS-Page gel stained with Coomassie blue.  Numbers are expressed 
in kDa. 
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Figure 14 
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15 µg of DNA per plate.  The yield of antibody using this amount of DNA was 
approximately 1.5 mg/L of HEK293T cells as determined by total protein concentration. 
 
To evaluate if the anti-DEC205-GyrA antibody was active towards thiolysis, the purified 
fusion was incubated with 100 mM sodium 2-mercaptoethanesulfonate (MESNA).  Two 
µl aliquots of the mixture were taken at 0, 2, 4, 8, 12, 24, and 48 hours.  These aliquots 
were loaded on a 12% SDS-page gel and stained with Coomassie blue to determine the 
extent of thiolysis at each time point.  Thiolysis was measured by the extent of cleavage 
of the GyrA intein which leaves the antibody with a reactive α-thioester on the heavy 
chain (Figure 6).  Acceptable levels of thiolysis by MESNA was achieved after 24 hour 
incubation (Figure 14C).  Since 48 hour incubation with MESNA did not improve the 
level of thiolysis, all subsequent experiments employed a 24 hour thiolysis step using 100 
mM MESNA.  All four antibodies tested with Mxe GyrA intein attached to its C-
terminus were able to be thiolysed using this protocol (Figure 14D).   
 
Next we designed an experiment to evaluate whether the DEC205 antibody thioester 
could undergo EPL. For this, we employed a short model peptide containing an N-
terminal cysteine (for ligation) and a fluorescein label to provide a convenient readout of 
ligation.  The DEC205 antibody thioester was incubated with 10 fold excess of short 
fluorescent peptide (Figure 15A).  The sample was run on a 12% SDS-Page gel with 
varying concentrations of short fluorescent peptides, which were used as standards.  The 
gel was then monitored for fluorescence. The fluorescent antibody band was then 
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compared to the intensity of short fluorescent peptide standards using ImageJ software 
(Figure 15B).  The ligation efficiency was determined to be ~98%. 
 
Commercially available amine-DNA (20-mer of As) was used to produce a DNA 
oligonucleotide with an N-terminal cysteine (Cys-DNA).  The amine-DNA was reacted 
with N-hydroxysuccimide activated Fmoc-Cys(StBu)-OH (Figure 10A).   The product 
was purified by HPLC, and the protecting groups (Fmoc and StBu) were removed by 
addition of 30% ammonium hydroxide and 1 M DTT.  The product was purified via 
HPLC and the identity of the compound was verified by MALDI-Mass Spectrometry 
(Figure 10B and 11).  A complimentary oligonucleotide (20-mer of Ts) was then 
annealed to the Cys-DNA. 
 
The double stranded (ds)-Cys-DNA was used for ligation to the MESNA-treated anti-
DEC205 antibody.  After an 18 hour reaction, the DNA-antibody conjugate was run on a 
2-20% TBE native gel stained with ethidium bromide to confirm ligation (Figure 16A).79  
A band was visualized around 1000 base pairs, which disappeared upon proteinase K 
treatment, indicating it was a DNA-antibody conjugate.  Ligation efficiency was 
indirectly approximated using a fluorescence assay.   
 
First, the MESNA-treated antibody was incubated with ds-Cys-DNA or unmodified 
DNA.  After overnight incubation, 10 fold excess of small fluorescent peptide was added 
to both reactions.  The samples were run on a 12% SDS-PAGE gel after an 18 hour 
incubation, and the amount of antibody that was fluorescently labeled was determined  
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Figure 15:  Ligation with Short Fluorescent Peptide.  A. Schematic of the Reaction of 
the MESNA-treated antibody with the short fluorescent peptide.  B.  Fluorescence assay 
to determine ligation efficiency.  100 pmoles of MESNA-treated DEC205 antibody was 
reacted with 1000 pmoles of the short fluorescent peptide.  The sample was run on a 10% 
SDS Page-gel and monitored for fluorescence.   The short fluorescent peptide was at 
varying concentrations in other lanes to use as standards of fluorescence.  ImageJ 
software was used to quantify the amount of fluorescent antibody. 
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using ImageJ software.  There was no difference seen between pretreatment of antibody 
with unmodified DNA and antibody that had no pretreatment (data not shown). Thus, the 
antibody treated with unmodified DNA was used as a control to represent 100% reaction 
with fluorescent peptide.  Anti-DEC205 antibody that was fluorescently labeled in the 
lane that was treated with Cys-DNA indicates the amount of antibody that did not react 
with the ds-Cys-DNA.  Thus, the amount of cys-DNA ligation was determined by 
subtracting the amount of fluorescence in the Cys-DNA treated lane from the amount of 
fluorescence in the unmodified DNA treated lane.  Ligation efficiencies for all the 
constructs ranged from 68-84%, with a typical ligation efficiency around 75% (Figure 
16C).    
 
This experiment assumes that there is no hydrolysis of the α-thioester on the MESNA-
treated DEC205 antibody during the initial reaction period.  This assumption seems 
reasonable since there was no difference in antibody fluorescence when the antibody is 
pretreated with unmodified DNA compared to no pre-treatment.  Furthermore, it is 
assumed that the same amount of thiolysis would occur during the initial reaction when 
comparing pretreatment with Cys-DNA and modified DNA as the only difference 
between the two reactions is the presence of the cystiene on the Cys-DNA.  
 
Only 20 base pairs of dA:dT were ligated to the anti-DEC antibody using EPL.  Ligation 
of longer Cys-DNA to the antibody was less efficient (data not shown), and production of 
longer cys-DNA was cost ineffective.  To introduce a larger dA:dT sequence into the 
antibody, since it has been shown that at least 40 base pairs of dA:dT are necessary for 
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immune activation of human MoDCs,28 Klenow fragment in the presence of ATP and 
TTP was used to elongate the double stranded DNA on the fusion mAb.84  A method was 
developed to elongate the DNA to approximately 250 base pairs, around the same length 
as commercially available poly dA:dT.  The DNA-antibody conjugate was then treated 
with proteinase K and run on a 2% agarose gel stained with EtBr to check for elongation  
(Figure 16B).  A length of 250 base pairs was seen after 90 minutes of Klenow reaction.  
Thus, this was the time point used to produce the anti-DEC205-poly dA:dT antibodies. 
 
We next wanted to verify that the anti-DEC205-poly dA:dT antibodies were still active.  
With the MESNA treatment during the production, disulfide bonds could have been 
reduced, impairing the functionality of the antibody. Thus, a CHO stain was performed.  
Three different concentrations of the anti-DEC205-poly dA:dT mAb was incubated with 
CHO cells that expressed either mouse or human DEC205 receptor or CHO cells that did 
not have the receptor (CHO NEO).  After incubation, antibodies bound to the CHO cells 
were labeled with either a mouse or human IgG-PE antibody.  FACS analysis was then 
performed to determine the extent of binding.  Results indicated that the antibodies bound 
specifically (to the CHO DEC205 cells, but not to the CHO NEO cells) and in a 
concentration dependent manner (Figure 17). 
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Figure 16:  DNA Ligation to DEC205 antibody.   A. MESNA-treated DEC205 or 
control mAb was added to Cys-DNA.  Production of DNA-mAb conjugates was 
monitored on a 2-20% TBE native gel stained with EtBr.  Numbers are expressed in base 
pairs.  B. Indirect determination of anti-DEC205-dA:dT mAb ligation efficiency.  After 
18 hour ligation reaction between Cys-DNA and DEC mAb-thioester, 1000 pmoles (20 
fold excess) of fluorescent peptide was added and allowed to react for a further 18 hours. 
The sample was run on a 10% SDS Page-gel and monitored for fluorescence.  ImageJ 
software was used to determine the amount of DEC antibody that was fluorescently 
labeled.  Numbers are in pmoles of fluorescent peptide.  C. Elongation of DNA.  Purified 
anti-DEC-dA:dT mAbs were reacted with Klenow fragment in the presence of dATP and 
dTTP.  The mAbs were treated with proteinase K and run on a 2% agarose gel stained 
with EtBr.  Numbers on left are expressed in base pairs.  Numbers on top represent time 
in min.  
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Figure 17:  CHO staining.  CHO cells with hDEC205 or mDEC205 receptors as well as 
CHO cells without DEC205 receptors (CHO NEO) were incubated with three different 
concentrations of anti-DEC205-poly dA:dT mAbs.  The cells were then stained with 
either anti-hIgG or anti-mIgG-PE antibody.  FACS analysis was performed to determine 
the extent of binding.  Top panel is for hDEC205 CHO cells.  Bottom panel is for 
mDEC205 CHO cells.  
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Production of Cys-SiRNA 
 
We wanted to determine if siRNA could be linked to the DEC205 antibody.  To test this, 
siRNA to programmed cell death ligand- 1 (PDL-1) was purchased from Sigma Aldrich 
(St. Louis, MO).  PDL-1 is a molecule that binds to its receptor, PD-1, found on activated 
T cells, B cells, and myeloid cells, to inhibit their activation.  Thus, by using siRNA to 
PDL-1, we wanted to determine if we could elicit a stronger immune response when an 
adjuvant and innate stimulus was given.   
 
We were able to produce Cys-siRNA using the method described for the production of 
cys-DNA above.  However, the yield was much lower, and not enough Cys-siRNA was 
made to attempt a ligation to the DEC205 antibody.  It was determined that the treatment 
with 30% Ammonium hydroxide was destroying the integrity of the siRNA and was the 
reason why so little was produced. 
 
The Cys-siRNA that was produced, however, was able to efficiently knockdown PDL-1 
(data not shown).  This indicates that the addition of the amino acid did not disrupt 
siRNA function. 
 
This project was abandoned, however, due to reproducibility issues.  The siRNA received 
from the company always consisted of varying purity.  Extraneous peaks were always 
seen in the HPLC trace before any chemistry was performed. 
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Immune Response of anti-hDEC205-poly dA:dT mAb in MoDCs 
 
Human MoDCs were treated with anti-hDEC-poly dA:dT and control Ig-poly dA:dT 
mAb to test for innate immunity (Figure 18A).  Anti-hDEC-poly dA:dT mAb caused 
production of IFN-α without the use of lipofectamine whereas anti-control-poly dA:dT 
mAb did not.  As expected, only cells treated with lipofectamine produced IFN-α when 
unconjugated poly dA:dT was given (Figure 18A).  The response was dependent on dose 
of anti-hDEC-poly dA:dT mAb (Figure 18A) and time of exposure (Figure 18B). To test 
the importance of hDEC receptor expression, MoDCs were pretreated with a high 
concentration (10 µg/ml) of anti-MHC II, anti-CD11c, anti-DEC205, and anti-IgG for 2 
hours.  After 2 hours, the cells were treated with the anti-hDEC-poly dA:dT mAb.  Only 
the pretreatment of anti-DEC205 mAb caused a significant decrease in the production of 
IFN-α by the MoDCs, indicating that the immune response was dependent on DEC205 
receptor expression (Figure 18C). 
 
To determine mechanism of immune activation, siRNA for RIG-I and MDA-5 was 
electroporated into the MoDCs on day 5 of their differentiation.85 On day 6, RNA was 
collected from the cells and converted into cDNA using High Capacity RNA-to-cDNA 
Kit (Applied Biosystems).  RT-PCR was then performed using the conditions and primer 
sequences previously described (Sasai et al., 2006).   Results of the RT-PCR indicated 
that there was sufficient knockdown with both the RIG-I and the MDA-5 siRNA.  Next, 
the supernatant from the siRNA treated MoDCs was collected and an IFN-α, TNF-α and 
IFN-β ELISA was performed.  Production of cytokines by anti-mDEC poly dA:dT mAb 
was significantly reduced with RIG-I siRNA whereas the MDA-5 siRNA had no effect 
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(Figure 19A, 19B, 19C).  This result implies that DEC205 allows for cross-presentation, 
and the poly dA:dT gains cytoplasmic entry to activate RIG-I. 
 
For comparison, other immune stimulants were given to the MoDCs.  hDEC-poly dA:dT 
mAb caused the most production of IFN-α and IFN-β when compared to poly IC (TLR 3 
and MDA-5 agonist), resiquimod (TLR 7/8 agonist), CLO75 (TLR 7/8 agonist), and LPS 
(TLR 4 agonist) (Figure 19A, C).  Anti-hDEC205-poly dA:dT mAb induced less TNF-α 
than resiquimod, CLO75, and LPS, but still a significant quantity (Figure 19B).  Thus, 
high quantities of type I IFN are produced and transfection agents are not necessary for 
immune stimulation by anti-DEC-poly dA:dT antibody, and we proceed to test this 
approach to stimulate innate and adaptive immunity in vivo in mice.   
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Figure 18:  Anti-DEC205-poly dA:dT mAb activates MoDCs.  A.  ELISA for the 
production of IFN-α (pg/mL) by MoDCs treated with various doses (5 ug/mL to 500 
ng/mL) of poly dA:dT, anti-hDEC-poly dA:dT mAb, and anti-hControl-poly dA:dT 
mAb. Graph is cumulative representation of 3 separate experiments.  Error bars show 
standard error of mean (SEM). B.  Time course of the production of IFN-β (pg/mL) by 
MoDCs treated with anti-hDEC-poly dA:dT mAb.  Y axis units are hours. Graph is 
cumulative representation of 2 separate experiments.  Error bars show SEM.   C.  MoDCs 
were pretreated for 2 hours with 10 µg of various mAbs before anti-DEC-poly dA:dT 
mAb was given.  ELISA was performed to determine IFN-α (pg/mL) production.  Y axis 
is amount of anti-DEC poly dA:dT mAb given (µg/mL) Graph is cumulative 
representation of 2 separate experiments.  Error bars show SEM. 
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Figure 19:  Anti-DEC205-poly dA:dT mAb activates RIG-I. A, B, & C.  ELISA for 
the production of IFN-α  (pg/mL) (A), TNF-α (ng/mL) (B), and IFN-β (pg/mL) (C) by 
MoDCs transfected by electroporation with control, MDA-5, or RIG-I specific siRNA, 
then stimulated with various immune stimulants including anti-hDEC205-poly dA:dT 
mAb. Graphs are cumulative representation of 3 separate experiments.  Error bars show 
SEM.    
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 Figure 19 
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Innate Immune Response in B6 Mice 
 
To show targeting, the anti-mDEC205-poly dA:dT antibody was labeled with Alexa 647.  
After injection of the labeled protein in naïve B6 mice, flow cytometry was performed to 
determine targeting.  The gating strategy is shown in figure 12.  The results show that 
anti-mDEC205-poly dA:dT mAb mostly targets to the CD8+ DCs.  There is also targeting 
to B cells, granulocytes, NK cells, and T cells.  There is very little targeting to CD8- DCs 
and red pulp macrophages, and no targeting to monocytes and plasmacytoid DCs (Figure 
20).   This is consistent with unconjugated anti-mDEC205 mAb. 
 
To determine the innate response of anti-mDEC205-poly dA:dT antibody, an IFN-α 
ELISA was performed on the serum of injected naïve B6 mice (Figure 21A).  
Gratifyingly, anti-mDEC205-poly dA:dT mAb caused as much IFN-α release as poly 
I:C.  The production of IFN-α by anti-mDEC205 poly dA:dT mAb was rapid in onset, 
occurring before three hours, and dose-dependent (Figure 21B).  As expected, this 
response was ablated in DEC205 knockout (KO) mice, and anti-mControl-dA:dT mAb 
did not cause innate immunity.    
 
To document the cellular source for IFN-α production, FACS was used to separate 
CD11clow plasmacytoid DC, CD8+ DC, and CD8- DC populations in the spleens of anti-
DEC-poly dA:dT mAb injected animals.  Only the CD8+ DCs produced IFN-α (Figure 
21C).  Although CD8+ DCs had more upregulation of CD40, CD86 and MHCII, all types 
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of DCs showed these features of “phenotypic” maturation (Figure 22A), indicating that 
all types of DCs responded to the cytokine made by the CD8+ DCs. 
 
To determine whether stromal cells were also producing IFN-α in response to anti-
mDEC205-poly dA:dT mAb, wild type or DEC KO mice were irradiated and then given 
bone marrow from a donor with the opposite genotype.  After 2 weeks, the mice were 
injected with anti-mDEC205-poly dA:dT mAb, and the innate immune response was 
determined using an IFN-α ELISA (Figure 22B).  Irradiated DEC205 KO mice with wild 
type bone marrow were able to produce significantly more IFN-α than irradiated wild 
type mice with DEC205 KO bone marrow, indicating that the majority of innate cytokine 
was produced from the bone marrow derived cells, namely the CD8+ DCs.  
 
To further demonstrate that the CD8+ DCs were responsible for the production of IFN-α, 
CD11c-DTR mice were injected with diptheria toxin (DT).  This knocks out all CD11c+ 
cells.  The next day, anti-mDEC205-poly dA:dT mAb was injected into the animals.  
Mice that received the DT were unable to produce cytokine as evidenced by ELISA 
(Figure 22C).   
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Figure 20. Targeting of anti-DEC205-poly dA:dT mAb.  Naïve B6 mice were injected 
with Alexa 647 labeled anti-mDEC205 poly dA:dT mAb. Uptake of labeled mAb by 
splenocytes was evaluated 3 hours after inoculation by multicolor flow cytometry.81  The 
gating strategy is shown in figure 12. 
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Figure 20  
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Figure 21. Anti-DEC205-poly dA:dT mAb induces an innate immune response in 
vivo driven solely by DEC+ CD8+ DCs.  A. B6 or DEC205 KO mice were inoculated 
i.p. with 10 µg of anti-mDEC-poly dA:dT mAb, anti-mControl-poly dA:dT mAb, or poly 
I:C.  After 6 hours, serum was collected and analyzed for IFN-α production using ELISA. 
Graph is cumulative representation of 5 separate experiments.  Error bars show SEM.     
B.  Various doses of anti-mDEC-poly dA:dT mAb were inoculated i.p. in B6 mice.  
Serum was collected at 3 and 6 hours and then analyzed for IFN-α production using 
ELISA. Graph is cumulative representation of 2 experiments with 3 mice each.  Error 
bars show SEM.  C.  B6 mice were inoculated i.p. with 10 µg of anti-mDEC-poly dA:dT 
mAb.  Splenocytes were harvested after 2 hours, and CD11clow, CD8+ DC, and CD8- DC 
populations were sorted using FACSAria with DiVa configuration.  The cells were plated 
overnight in RPMI supplemented with 5% FCS, and the supernatant was collected for an 
IFN-α ELISA. Graph is cumulative representation for 1 experiment with 4 mice.  Error 
bars show SEM. 
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Anti-Control-poly dA:dT mAb 
IFN-α  Release (pg/ml) 
Poly I:C 
Anti-DEC205-poly dA:dT mAb 
B6 Wildtype 
Mouse 
DEC205 Knockout 
Mouse 
Anti-DCIR2-poly dA:dT mAb 
0 100 200 400 
IFN-α  Release (pg/ml) 
500 300 
0.3 µg 
1 µg 
3 µg 
10 µg 
3 Hour Treatment 
6 Hour Treatment 
CD11c Low Cells 
CD8– Dendritic Cells 
CD8+ Dendritic Cells 
IFN-α  Release (pg/ml) 
0 100 200 150 50 
Anti-DEC205-poly dA:dT mAb 
Anti-Control-poly dA:dT mAb 
B 
A 
C 
 96 
 
 
 
 
 
 
 
 
 
 
Figure 22. Maturation, Chimeras, and CD11c DTR mice.  A.  B6 mice were 
stimulated with 10 µg of anti-mDEC-poly dA:dT mAb or PBS.  Maturation of CD8+ 
DCs, CD8- DCs, and PDCA-1+ PDCs was evaluated 12 hours after injection by 
multicolor flow cytometry.  The gating strategy for these DC subsets is shown if figure 
12.  B. Wild type or DEC KO mice were irradiated and then given bone marrow from a 
donor with the opposite genotype (i.e. B6 → DEC KO is wild type bone marrow into 
irradiated DEC KO mouse).  After 2 weeks, the mice were stimulated with 10 µg of 
Alexa 647 labeled anti-mDEC-poly dA:dT mAb, and serum was collected 6 hours later 
for an IFN-α ELISA.  Uptake of labeled mAb splenocytes was also evaluated in these 
mice by multicolor flow cytometry in CD8+ and CD8- DCs. Graph is cumulative 
representation for 2 experiments with 3 mice each.  Error bars show SEM. C.  CD11c 
DTR mice were injected with diptheria toxin.  The next day, anti-mDEC-poly dA:dT 
mAb was injected into the animals.  Serum was harvested after 6 hours and an IFN- α 
ELISA was performed. Graph is cumulative representation for 1 experiment with 3 mice.  
Error bars show SEM. 
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Figure 22  
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Adaptive Immune Response in B6 Mice 
 
To test its potential to induce adaptive immunity, anti-DEC205-poly dA:dT mAb was 
injected together with anti-DEC205-HIV Gag p24 mAb. The latter efficiently immunizes 
mice when an adjuvant acting systemically, such as poly I:C, is co-administered 
Trumpfheller et al., 2006).  After prime/boost immunization, splenocytes were 
restimulated with 15-mer overlapping peptide mixes spanning the sequence of both Gag 
p24 and control Gag p17 proteins.  T-cells were then monitored for IFN-γ production 
(Figure 23).  The results indicated that a significantly higher amount of IFN-γ was 
produced from immune T-cells when 15 µg anti-mDEC205-poly dA:dT mAb was 
delivered compared to 15 µg of poly I:C.  Furthermore, since the poly dA:dT composes 
only half of the antibody-DNA conjugate, an even greater immune response was seen 
when anti-mDEC205-poly dA:dT mAb was compared to 7.5 µg of poly I:C (Figure 23). 
 
To test if anti-DEC targeted dA:dT could serve as an adjuvant for Gag targeted within 
another mAb to this DC subset, we used anti-Langerin-HIV Gag p24 mAb instead of 
anti-DEC205-Gag p24 mAb.  Langerin, like DEC205, is a C-type lectin receptor.  It has 
been shown that anti-Langerin mAb targets selectively to CD8+ DCs and that adaptive 
immunity can be elicited when anti-Langerin mAb is used to target antigens.   When the 
above experiment was performed, immunization did occur, but less than with anti-
DEC205 targeted Gag p24 probably because Langerin is not abundant on cross 
presenting DCs in lymphoid organs of B6 mice (Figure 24).   
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We suspected that both the adjuvant and antigen would need to be targeted to the same 
DC subset for immunization to proceed.  To test this hypothesis, HIV Gag p24 antigen 
was delivered specifically to CD8- DCs using an antibody to DCIR2 in conjunction with 
anti-DEC205-poly dA:dT mAb.  Unexpectedly, a large number of IFN-γ producing T-
cells was seen, even more so than with anti-DEC205-HIV gag p24 mAb.  Thus, as seen 
in Figure 22A, the cytokine production from the CD8+ DCs is able to mature the CD8- 
DCs to allow for immunization to occur.  A more robust response is seen probably 
because anti-DCIR2 mAb is better at inducing CD4+ T cells as shown previously 
(Dudziak et al., 2007). 
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Figure 23. Adaptive Immunity using anti-DEC205-Gag p24 mAb.   C57BL/6 mice 
were primed and boosted 4 wk apart with HIV gag p24 antigen conjugated to anti-
DEC205 mAb.  Anti-DEC-poly dA:dT mAb, poly I:C, anti-control-poly dA:dT mAb, or 
anti-DCIR2-poly dA:dT mAb was used as the adjuvant for the immunizations.  IFN-γ 
secretion in gated CD3+CD4+ splenic T cells in response to HIV gag p24 peptides was 
measured 1 wk after boost.  Top is schematic of procedure.  Middle is histogram 
representing cumulative data of 3 experiments with 3 mice each.  Error bars represent 
SEM.  Bottom are respresentative FACS plots for each group.  
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Figure 23 
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Figure 24: Adaptive Immunity using anti-DEC205-poly dA:dT mAb.  a, C57BL/6 
mice were primed and boosted 4 wk apart with HIV gag p24 antigen conjugated to anti-
DEC205 mAb, anti-Langerin mAb, or Anti-DCIR2-mAb.  Anti-DEC-poly dA:dT mAb  
was used as the adjuvant for the immunizations.  IFN-γ secretion in gated CD3+CD4+ 
splenic T cells in response to HIV gag p24 peptides was measured 1 wk after boost. 
Middle is histogram representing cumulative data of 2 experiments with 3 mice each.  
Error bars represent SEM.  Top is schematic of procedure.  Bottom are respresentative 
FACS plots for each group. 
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Figure 24 
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Anti-DCIR2-poly dA:dT mAb 
 
DCIR2 is another C-type lectin receptor.  It has been shown to target exclusively to CD8- 
DCs. To explore whether the targeting of poly dA:dT to CD8- DCs could also cause 
immunity, anti-DCIR2-poly dA:dT mAbs were produced (Figure 25).  Although the 
fusion mAb specifically bound to CHO cells stably expressing the DCIR2 receptor, 
injection of anti-DCIR2-poly dA:dT mAb did not initiate innate immunity (Figure 21A).  
We also tested if adaptive immunity would develop if anti-DCIR2-poly dA:dT mAb was 
given as an adjuvant with anti-DCIR2, anti-DEC205 or anti-Langerin-HIV Gag p24 
mAbs.  An immune response was not seen in any case tested (Figure 23). 
 
To investigate the cause of anti-DCIR2-poly dA:dT mAb ineffectiveness, FACs was used 
to sort plasmacytoid DCs (PDCs), CD8+ DCs, and CD8- DCs from wildtype B6 mice.  
Poly dA:dT with lipofectamine, poly I:C with and without lipofectamine, anti-DEC205-
poly dA:dT mAb, and anti-DCIR2-poly dA:dT mAb were then given to the sorted cells in 
vitro (Figure 26A).  As published previously, only the CD8+ DCs produced IFN-α when 
poly I:C was given without lipofectamine.  All subsets were able to produce IFN-α when 
poly dA:dT or poly I:C was given in conjunction with lipofectamine.  However, only the 
CD8+ DCs were able to be stimulated by anti-mDEC205-poly dA:dT mAb, and none of 
the cells were able to respond to anti-DCIR2-poly dA:dT mAb (Figure 26A).  Since CD8- 
DCs respond to poly dA:dT when given with lipofectamine, we conclude that poly dA:dT 
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is not delivered to the cytoplasm in the CD8- DCs and therefore does not cause immune 
activation. 
 
To further test this hypothesis, human DEC205 CD11c mice were used.  These mice 
express human DEC205 on both CD8- and CD8+ DCs.  When these mice were treated 
with anti-hDEC205-poly dA:dT mAb, only the CD8+ DCs were able to elicit an immune 
response (Figure 26B).  This further supports that the CD8+ cross-presenting DCs are 
needed to allow cytoplasmic entry of the poly dA:dT. 
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Figure 25.  Production of anti-DCIR2-poly dA:dT mAbs.  A.B,  The integrity of the 
anti-DCIR2-intein mAb was confirmed by 10% SDS-Page gel stained with (A) 
Coomassie blue and (B) Western blot analysis using goat anti-mouse IgG Ab conjugated 
with HRP.  Numbers are expressed in kDa.  C. Thiolysis of the DCIR2 mAb.  Anti-
DCIR2-intein mAbs were treated with 100 mM MESNA for 18 hours.  The removal of 
the intein from the heavy chain was confirmed by 10% SDS-Page gel stained with 
Coomassie blue.  Numbers are expressed in kDa.  D. DNA ligation to antibody.  
MESNA-treated DCIR2 mAb was added to Cys-DNA.  Production of DNA-mAb 
conjugates was monitored on a 2-20% TBE native gel stained with EtBr.  E.  Elongation 
of DNA.  Purified anti-DCIR2-dA:dT mAbs were reacted with Klenow fragment in the 
presence of dATP and dTTP.  The mAbs were treated with proteinase K and run on a 2% 
agarose gel stained with EtBr.  Numbers on left are expressed in base pairs.  Numbers on 
top represent time in min.  F. Indirect determination of anti-DCIR2-dA:dT mAb ligation 
efficiency.  After 18 hour ligation reaction between cys-DNA and activated DCIR2 mAb, 
1000 pmoles (20 fold excess) of fluorescent peptide was added and allowed to react for a 
further 18 hours. The sample was run on a 10% SDS Page-gel and monitored for 
fluorescence.  ImageJ software was used to determine the amount of DCIR2 antibody that 
was fluorescently labeled.  Numbers are in pmoles of fluorescent peptide.  G. CHO cells 
with DCIR2 receptor as well as CHO NEO cells were incubated with three different 
concentrations of anti-DCIR2-poly dA:dT mAbs.  The cells were then stained with anti-
mIgG-PE antibody.  FACS analysis was performed to determine the extent of binding. 
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Figure 25 
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Figure 26.  CD8+ DCs are needed for cytoplasmic entry of poly dA:dT.  A,B.  CD8+, 
CD8-, and PDCs were sorted from either wildtype (A) or human DEC CD11c mice (B).   
Cells were plated at 300,000 cells/mL and then stimulated with various immune 
stimulants with or without the use of lipofectamine.  An IFN-α ELISA was performed on 
the cell’s supernatant the following day.   
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Figure 26 
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Chapter 4 
 
Discussion 
 
Introduction 
Ralph M. Steinman and Zanvil A. Cohn first described dendritic cells in 1973, and the 
new cells were characterized by their morphology and excellence at inducing immune 
reactions (Steinman et al., 1978). It took many years and compelling evidence to 
convince the scientific community that DCs were distinct from macrophages.  The main 
function of DCs is to present antigen to T cells, controlling both tolerance and immunity.  
Antigens have been successfully delivered to DCs using uptake receptors, like DEC205, 
to induce both tolerance and immunity (Hawiger, et al., 2001).  In terms of immunity, it 
has been shown that direct delivery of an antigen to DCs produces an immune response 
100 to 1000 times greater than untargeted antigen (Trumpfheller et al., 2006).  To mature 
DCs, however, an adjuvant is necessary in these experiments.   
 
Although antigens have been targeted specifically to DCs using a variety of uptake 
receptors, adjuvants have always been given systemically.  In fact, it was shown that poly 
I:C, the most commonly used adjuvant to induce CD4+ T cell immunity, acts mostly on 
non-hematopoietic cells (Longhi et al., 2009).  Thus, it was believed that a systemic 
immune response was required to induce immunity, and DCs were not capable of 
inducing adaptive immunity alone.   
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To test this hypothesis, we were able to ligate poly dA:dT, a type I interferon immune 
stimulant, to an antibody to the DEC205 receptor.  We show that the anti-DEC205-poly 
dA:dT mAbs target to CD8+ DCs, and these cells are able to produce IFN-α in response.  
The response was shown to be RIG-I dependent in human MoDCs, indicating that the 
poly dA:dT is entering the cytoplasm, probably through the same mechanism as cross-
presentation.  We also demonstrate that DCs are sufficient to induce adaptive immunity 
when both the adjuvant (poly dA:dT) and antigen (Gag p24) are delivered exclusively to 
them.   
 
There are three major findings discussed in this thesis.   First, the method to ligate DNA 
to the DEC205 antibody is novel.  Furthermore, we were able to elongate the DNA to 
produce poly dA:dT.  Second, we illustrate that CD8+ DCs are sufficient to induce innate 
and adaptive immunity in vivo when antigen and adjuvant are targeted selectively to 
them.  Finally, the thesis provides insight to the mechanism of cross-presentation. 
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Implication of Anti-DEC205-poly dA:dT mAb Production 
DNA-antibody conjugates have been created since 1992 where the first immuno-PCR 
was described (Sano et al., 1992). In these experiments, the antibody is used to detect 
some antigen, and the DNA moiety is used to increase detection by PCR amplification 
(Fredriksson et al., 2002, Hendrickson et al., 1995, and Mckie et al., 2002). However, 
immuno-PCR has not gained wide use, mainly because of the antibody’s molecular 
heterogeneity and lack of precise chemical control at the site of DNA attachment. 
 
EPL has been used in the production of DNA-protein conjugates for immuno-PCR since 
2005 (Burbulis et al., 2005).  Termed “tadpoles,” these DNA-protein conjugates are 
homogenous and the DNA molecules are added to the protein of interest in a site-specific 
manner.   However, due to ease of production, only proteins of interest that could be 
expressed in bacteria, such as streptavidin (Sydor et al., 2002) and single-chain 
antibodies, (Ruelen et al., 2009) were used to produce tadpoles.    
 
The use of antibodies as the protein of interest for EPL was not described until 2011 
(Mohlmann et al., 2011).  In this work, EPL was used to link an extra domain of 
fibronectin (ED-B) antibody to biotin.  ED-B containing fibronectin is associated with 
angiogenesis and tissue remodeling (Menrad et al., 2005), and high levels of ED-B have 
been detected in solid tumors (Borsi et al., 2002 and Santimaria et al., 2003).  The 
researchers of this article want to eventually use EPL to link cytotoxic agents to ED-B 
antibody as an antibody-based cancer treatment.   However, in these experiments, EPL 
was not used to link the antibody of interest to DNA. 
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The approach described in this thesis offers a novel way to produce DNA-antibody 
conjugates.  EPL has never been used to create DNA-full length antibody conjugates 
before.  Thus, this method provides a new way to prepare DNA-antibody conjugates 
where there is defined stoichiometry and regioselectivity at the coupling site.  This is 
ideal for immuno-PCR.  With this method, full-length antibodies (not just single-chain 
antibodies) can be utilized, making it possible to target a wider variety of proteins of 
interest in the assay.   
 
There are other applications for the production of DNA-antibody conjugates using this 
method.  One idea is to use the method to target siRNA.  One of the hardest obstacles to 
overcome when using siRNA is cell delivery.  Transfection agents are needed to allow 
for cell entry.  Furthermore, specific cells cannot be targeted by siRNAs; siRNA will 
knockdown the gene of interest in all cells it enters.  By linking the siRNA to an antigen 
uptake receptor antibody, the siRNA will have ease of entry and will target specific cells.  
Of note, this method will probably only work for cells that undergo cross-presentation to 
allow the siRNA to enter the cytoplasm of the targeted cell. 
 
One of the disadvantages to the method described above was that only short ds-DNA was 
linked to the antibody.  Longer Cys-DNA had lower ligation efficiency to the DEC205 
antibody.  We overcome this obstacle by elongating the DNA that was attached to the 
antibody using Klenow Fragment.  This is the first description of elongating DNA that is 
attached to an antibody.  The sequence of elongation, however, is not specific.  Since we 
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were ligating poly dA:dT, this was not an issue in our case, but the method is limited for 
researchers who wish to add longer, sequence specific DNA to antibodies. 
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CD8+ DCs are Sufficient to Induce Innate and Adaptive Immunity 
DC activation is not a linear process, and the nature, intensity, and duration of the 
activation signal are important in determining effector function of DCs (Kapsenberg et 
al., 2003). As such, it was hypothesized that inflammatory cytokines could represent the 
actual mediators of DC activation in vivo and may serve to trigger adaptive immune 
reactions in response to pathogens that fail to engage DC-expressed pattern-recognition 
receptors (Reis e Sousa et al., 2005). 
 
However, researchers reported that indirect activation by inflammatory mediators 
generated DCs that supported CD4+ T cell clonal expansion but failed to direct T helper 
cell differentiation (Reis e Sousa et al., 2005 and Nolte et al., 2007).  Only direct 
exposure of pathogen components, such as CpG-containing DNA or LPS, resulted in 
fully activated DCs that promoted T helper responses (Reis e Sousa et al., 2005)  
Moreover, cytokines originating from nonhematopoietic cells were neither sufficient nor 
required for DC activation in vivo (Nolte et al, 2007).   
 
When mice are injected with poly I:C, a synthetic double stranded RNA agonist for 
TLR3 and MDA-5, type I interferon was rapidly produced as an innate response, and this 
acts on DCs as a component of adjuvant action for adaptive immunity.  
Nonhematopoietic cells produce the bulk of the innate type I interferon, and both DCs 
and nonDCs are required for immunization to proceed (Longhi et al., 2009).  However, 
innate stimuli have not been selectively delivered to DCs to determine if these cells alone 
are capable of integrating innate and adaptive immunity in the intact animal.   
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The results of this thesis indicate that CD8+ DCs are sufficient to induce innate immunity.  
First, it is shown that the anti-DEC205-poly dA:dT mAb’s main target is the CD8+ DCs 
(Figure 20).  Further proof of selective targeting is that only the CD8+ DCs produce type 
I interferon when stimulated with anti-DEC205-poly dA:dT mAb in vitro (Figure 25) and 
ex vivo (Figure 21C).  The mouse chimera experiment indicates that type I interferon 
production from nonhematopoietic cells, i.e. stromal cells, is minimal (Figure 22B).  
Thus, this is the first proof that selective targeting of CD8+ DCs is sufficient to induce 
innate immunity (Figure 21A). 
 
Using anti-DEC205-poly dA:dT mAb as the adjuvant and anti-DEC205-Gag p24 mAb or 
anti-Langerin-Gag p24 mAb as the antigen, we selectively targeted CD8+ DCs.  The 
results indicated that selective targeting to CD8+ DCs was sufficient in inducing an 
adaptive immune response as evidenced by the number of CD4+ IFN-γ producing T-cells 
(Figure 23 and 24).  This result was specific as anti-control-poly dA:dT mAb did not 
induce immunity, and the immunity induced was stronger than when poly I:C was given 
at a similar dose (Figure 23).   Poly I:C did work better when a larger does was used as an 
adjuvant, however.  This is probably due to the fact that there are more stromal cells than 
dendritic cells in the intact animal.  Thus, if a larger dose of poly I:C is given, more IFN-
α can be produced than when the immune stimulant is targeted only to DCs.   
 
One surprising experiment is that when the adjuvant was targeted to CD8+ DCs and the 
antigen was targeted to CD8- DCs using anti-DCIR2-Gag p24 mAb, adaptive immunity 
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was elicited (Figure 24).  Previous results indicated that cytokines alone are not sufficient 
to induce immunity and that the immune cell must have direct exposure to the adjuvant.  
However, our results indicated that the cytokine produced from the CD8+ DCs was 
sufficient to induce the phenotypic changes used to depict DC maturation in both PDCs 
and CD8- DCs (Figure 22A).  Furthermore, the in vitro results using the sorted mouse 
DCs indicated that poly I:C has difficulty entering the cells; a much greater immune 
response was seen when poly I:C was given with lipofectamine than when it was given 
without (Figure 26).  Previous work has also shown that the majority of cytokine is 
produce from the nonhematopoietic cells when poly I:C is injected into mice. Thus, it is 
likely that for CD4+ T cell immunity, the adjuvant is needed to induce type I interferon, 
but is not required to directly stimulate the DCs. 
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Implications for Cross-Presentation 
 
Although it is known that the DEC receptor is capable of cross-presentation, the 
mechanism is not well understood ((Dudziak et al., 2007).   Two theories have been 
proposed.  The first theory hypothesizes that cross-presenting DCs have specialized 
phagosomes that contain MHC class I machinery.  Hence, the endocytosed antigen does 
not have to compete with loading of endogenous peptides in the ER, but instead would be 
brought to these phagosomes for MHC class I peptide presentation (Guermonprez et al., 
2003). The second theory proposes that cross-presenting DCs possess the machinery for 
antigen escape from endosome into the cytoplasm to gain access to the proteasome and 
TAP transporters (Dudziak et al., 2007). 
 
Our results support the latter theory.   The production of type I interferon is reduced with 
the use of RIG-I siRNA in human monocyte derived DCs (Figure 19).  Thus, the poly 
dA:dT must be delivered to the cytoplasm of the DC after endocytosis in order to cause 
immune stimulation.   
 
The use of anti-DCIR2-poly dA:dT mAb also provides insight to the mechanism of cross-
presentation.  Anti-DCIR2-poly dA:dT mAb was unable to induce innate or adaptive 
immunity, even though the antibody was shown to be functional by CHO staining (Figure 
25G).  We thought that the reason for this was that CD8- DCs were unable to respond to 
poly dA:dT.  This was not the case, however, as shown in the in vitro experiment where 
CD8- DCs responded to poly dA:dT given with lipofectamine (Figure 26A).  This lead us 
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to the hypothesis that the poly dA:dT was not being delivered to the cytoplasm because 
the CD8- DCs cannot cross-present. 
 
To test this hypothesis, human DEC205 CD11c transgenic mice were used.  Human 
DEC205 is expressed on both CD8+ and CD8- DCs in these animals.  When given anti-
hDEC205-poly dA:dT mAb, only the CD8+ DCs were able to produce type I interferon 
(Figure 26B).  Thus, cross-presentation is not receptor dependent, but cell type 
dependent.  The CD8+ DCs must express some proteins that allow its endocytosed 
material into the cytoplasm.  The names of these proteins still remain to be identified. 
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